Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer

Non-small cell lung carcinoma (NSCLC) comprises 80%–85% of lung cancer cases. EGFR is involved in several cancer developments, including NSCLC. The EGFR pathway regulates the Bax/Bcl-2 cascade in NSCLC. Increasing understanding of the molecular mechanisms of fundamental tumor progression has guided...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 869672
Main Authors Alam, Manzar, Alam, Shoaib, Shamsi, Anas, Adnan, Mohd, Elasbali, Abdelbaset Mohamed, Al-Soud, Waleed Abu, Alreshidi, Mousa, Hawsawi, Yousef MohammedRabaa, Tippana, Anitha, Pasupuleti, Visweswara Rao, Hassan, Md. Imtaiyaz
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 25.03.2022
Subjects
apoptosis
B cell lymphoma 2
Bax
NSCLC
Oncology
signaling
targeted therapy
B cell lymphoma 2
Bax
targeted therapy
apoptosis
signaling
NSCLC
Online AccessGet full text
ISSN2234-943X
2234-943X
DOI10.3389/fonc.2022.869672

Cover

Abstract Non-small cell lung carcinoma (NSCLC) comprises 80%–85% of lung cancer cases. EGFR is involved in several cancer developments, including NSCLC. The EGFR pathway regulates the Bax/Bcl-2 cascade in NSCLC. Increasing understanding of the molecular mechanisms of fundamental tumor progression has guided the development of numerous antitumor drugs. The development and improvement of rationally planned inhibitors and agents targeting particular cellular and biological pathways in cancer have been signified as a most important paradigm shift in the strategy to treat and manage lung cancer. Newer approaches and novel chemotherapeutic agents are required to accompany present cancer therapies for improving efficiency. Using natural products as a drug with an effective delivery system may benefit therapeutics. Naturally originated compounds such as phytochemicals provide crucial sources for novel agents/drugs and resources for tumor therapy. Applying the small-molecule inhibitors (SMIs)/phytochemicals has led to potent preclinical discoveries in various human tumor preclinical models, including lung cancer. In this review, we summarize recent information on the molecular mechanisms of the Bax/Bcl-2 cascade and EGFR pathway in NSCLC and target them for therapeutic implications. We further described the therapeutic potential of Bax/Bcl-2/EGFR SMIs, mainly those with more potent and selectivity, including gefitinib, EGCG, ABT-737, thymoquinone, quercetin, and venetoclax. In addition, we explained the targeting EGFR pathway and ongoing in vitro and in vivo and clinical investigations in NSCLC. Exploration of such inhibitors facilitates the future treatment and management of NSCLC.
AbstractList Non-small cell lung carcinoma (NSCLC) comprises 80%-85% of lung cancer cases. EGFR is involved in several cancer developments, including NSCLC. The EGFR pathway regulates the Bax/Bcl-2 cascade in NSCLC. Increasing understanding of the molecular mechanisms of fundamental tumor progression has guided the development of numerous antitumor drugs. The development and improvement of rationally planned inhibitors and agents targeting particular cellular and biological pathways in cancer have been signified as a most important paradigm shift in the strategy to treat and manage lung cancer. Newer approaches and novel chemotherapeutic agents are required to accompany present cancer therapies for improving efficiency. Using natural products as a drug with an effective delivery system may benefit therapeutics. Naturally originated compounds such as phytochemicals provide crucial sources for novel agents/drugs and resources for tumor therapy. Applying the small-molecule inhibitors (SMIs)/phytochemicals has led to potent preclinical discoveries in various human tumor preclinical models, including lung cancer. In this review, we summarize recent information on the molecular mechanisms of the Bax/Bcl-2 cascade and EGFR pathway in NSCLC and target them for therapeutic implications. We further described the therapeutic potential of Bax/Bcl-2/EGFR SMIs, mainly those with more potent and selectivity, including gefitinib, EGCG, ABT-737, thymoquinone, quercetin, and venetoclax. In addition, we explained the targeting EGFR pathway and ongoing in vitro and in vivo and clinical investigations in NSCLC. Exploration of such inhibitors facilitates the future treatment and management of NSCLC.Non-small cell lung carcinoma (NSCLC) comprises 80%-85% of lung cancer cases. EGFR is involved in several cancer developments, including NSCLC. The EGFR pathway regulates the Bax/Bcl-2 cascade in NSCLC. Increasing understanding of the molecular mechanisms of fundamental tumor progression has guided the development of numerous antitumor drugs. The development and improvement of rationally planned inhibitors and agents targeting particular cellular and biological pathways in cancer have been signified as a most important paradigm shift in the strategy to treat and manage lung cancer. Newer approaches and novel chemotherapeutic agents are required to accompany present cancer therapies for improving efficiency. Using natural products as a drug with an effective delivery system may benefit therapeutics. Naturally originated compounds such as phytochemicals provide crucial sources for novel agents/drugs and resources for tumor therapy. Applying the small-molecule inhibitors (SMIs)/phytochemicals has led to potent preclinical discoveries in various human tumor preclinical models, including lung cancer. In this review, we summarize recent information on the molecular mechanisms of the Bax/Bcl-2 cascade and EGFR pathway in NSCLC and target them for therapeutic implications. We further described the therapeutic potential of Bax/Bcl-2/EGFR SMIs, mainly those with more potent and selectivity, including gefitinib, EGCG, ABT-737, thymoquinone, quercetin, and venetoclax. In addition, we explained the targeting EGFR pathway and ongoing in vitro and in vivo and clinical investigations in NSCLC. Exploration of such inhibitors facilitates the future treatment and management of NSCLC.
Non-small cell lung carcinoma (NSCLC) comprises 80%-85% of lung cancer cases. EGFR is involved in several cancer developments, including NSCLC. The EGFR pathway regulates the Bax/Bcl-2 cascade in NSCLC. Increasing understanding of the molecular mechanisms of fundamental tumor progression has guided the development of numerous antitumor drugs. The development and improvement of rationally planned inhibitors and agents targeting particular cellular and biological pathways in cancer have been signified as a most important paradigm shift in the strategy to treat and manage lung cancer. Newer approaches and novel chemotherapeutic agents are required to accompany present cancer therapies for improving efficiency. Using natural products as a drug with an effective delivery system may benefit therapeutics. Naturally originated compounds such as phytochemicals provide crucial sources for novel agents/drugs and resources for tumor therapy. Applying the small-molecule inhibitors (SMIs)/phytochemicals has led to potent preclinical discoveries in various human tumor preclinical models, including lung cancer. In this review, we summarize recent information on the molecular mechanisms of the Bax/Bcl-2 cascade and EGFR pathway in NSCLC and target them for therapeutic implications. We further described the therapeutic potential of Bax/Bcl-2/EGFR SMIs, mainly those with more potent and selectivity, including gefitinib, EGCG, ABT-737, thymoquinone, quercetin, and venetoclax. In addition, we explained the targeting EGFR pathway and ongoing and and clinical investigations in NSCLC. Exploration of such inhibitors facilitates the future treatment and management of NSCLC.
Non-small cell lung carcinoma (NSCLC) comprises 80%–85% of lung cancer cases. EGFR is involved in several cancer developments, including NSCLC. The EGFR pathway regulates the Bax/Bcl-2 cascade in NSCLC. Increasing understanding of the molecular mechanisms of fundamental tumor progression has guided the development of numerous antitumor drugs. The development and improvement of rationally planned inhibitors and agents targeting particular cellular and biological pathways in cancer have been signified as a most important paradigm shift in the strategy to treat and manage lung cancer. Newer approaches and novel chemotherapeutic agents are required to accompany present cancer therapies for improving efficiency. Using natural products as a drug with an effective delivery system may benefit therapeutics. Naturally originated compounds such as phytochemicals provide crucial sources for novel agents/drugs and resources for tumor therapy. Applying the small-molecule inhibitors (SMIs)/phytochemicals has led to potent preclinical discoveries in various human tumor preclinical models, including lung cancer. In this review, we summarize recent information on the molecular mechanisms of the Bax/Bcl-2 cascade and EGFR pathway in NSCLC and target them for therapeutic implications. We further described the therapeutic potential of Bax/Bcl-2/EGFR SMIs, mainly those with more potent and selectivity, including gefitinib, EGCG, ABT-737, thymoquinone, quercetin, and venetoclax. In addition, we explained the targeting EGFR pathway and ongoing in vitro and in vivo and clinical investigations in NSCLC. Exploration of such inhibitors facilitates the future treatment and management of NSCLC.
Non-small cell lung carcinoma (NSCLC) comprises 80%–85% of lung cancer cases. EGFR is involved in several cancer developments, including NSCLC. The EGFR pathway regulates the Bax/Bcl-2 cascade in NSCLC. Increasing understanding of the molecular mechanisms of fundamental tumor progression has guided the development of numerous antitumor drugs. The development and improvement of rationally planned inhibitors and agents targeting particular cellular and biological pathways in cancer have been signified as a most important paradigm shift in the strategy to treat and manage lung cancer. Newer approaches and novel chemotherapeutic agents are required to accompany present cancer therapies for improving efficiency. Using natural products as a drug with an effective delivery system may benefit therapeutics. Naturally originated compounds such as phytochemicals provide crucial sources for novel agents/drugs and resources for tumor therapy. Applying the small-molecule inhibitors (SMIs)/phytochemicals has led to potent preclinical discoveries in various human tumor preclinical models, including lung cancer. In this review, we summarize recent information on the molecular mechanisms of the Bax/Bcl-2 cascade and EGFR pathway in NSCLC and target them for therapeutic implications. We further described the therapeutic potential of Bax/Bcl-2/EGFR SMIs, mainly those with more potent and selectivity, including gefitinib, EGCG, ABT-737, thymoquinone, quercetin, and venetoclax. In addition, we explained the targeting EGFR pathway and ongoing in vitro and in vivo and clinical investigations in NSCLC. Exploration of such inhibitors facilitates the future treatment and management of NSCLC.
Author Hawsawi, Yousef MohammedRabaa
Elasbali, Abdelbaset Mohamed
Alam, Shoaib
Al-Soud, Waleed Abu
Alam, Manzar
Pasupuleti, Visweswara Rao
Alreshidi, Mousa
Hassan, Md. Imtaiyaz
Shamsi, Anas
Adnan, Mohd
Tippana, Anitha
AuthorAffiliation 1 Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia , Jamia Nagar , India
9 Regional Agricultural Research Station, Acharya N. G. Ranga Agricultural University (ANGRAU) , Tirupati , India
8 Research Center, King Faisal Specialist Hospital and Research Center , Jeddah , Saudi Arabia
3 Department of Biology, College of Science, University of Hail , Hail , Saudi Arabia
2 Department of Biotechnology, Jamia Millia Islamia , Jamia Nagar , India
4 Department of Clinical Laboratory Science, College of Applied Sciences-Qurayyat, Jouf University , Sakaka , Saudi Arabia
6 Health Sciences Research Unit, Jouf University , Sakaka , Saudi Arabia
11 Department of Biochemistry, Faculty of Medicine and Health Sciences, Abdurrab University , Pekanbaru , Indonesia
7 Molecular Diagnostics and Personalized Therapeutics Unit, University of Hail , Hail , Saudi Arabia
12 Centre for International Collaboration and Research, Reva University, Rukmini Knowledge Park , Bangalore , India
5 Departme
AuthorAffiliation_xml – name: 2 Department of Biotechnology, Jamia Millia Islamia , Jamia Nagar , India
– name: 12 Centre for International Collaboration and Research, Reva University, Rukmini Knowledge Park , Bangalore , India
– name: 4 Department of Clinical Laboratory Science, College of Applied Sciences-Qurayyat, Jouf University , Sakaka , Saudi Arabia
– name: 3 Department of Biology, College of Science, University of Hail , Hail , Saudi Arabia
– name: 7 Molecular Diagnostics and Personalized Therapeutics Unit, University of Hail , Hail , Saudi Arabia
– name: 6 Health Sciences Research Unit, Jouf University , Sakaka , Saudi Arabia
– name: 10 Department of Biomedical Sciences and Therapeutics, Faculty of Medicine & Health Sciences, University Malaysia Sabah , Kota Kinabalu , Malaysia
– name: 8 Research Center, King Faisal Specialist Hospital and Research Center , Jeddah , Saudi Arabia
– name: 5 Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Jouf University , Sakaka , Saudi Arabia
– name: 11 Department of Biochemistry, Faculty of Medicine and Health Sciences, Abdurrab University , Pekanbaru , Indonesia
– name: 1 Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia , Jamia Nagar , India
– name: 9 Regional Agricultural Research Station, Acharya N. G. Ranga Agricultural University (ANGRAU) , Tirupati , India
Author_xml – sequence: 1
  givenname: Manzar
  surname: Alam
  fullname: Alam, Manzar
– sequence: 2
  givenname: Shoaib
  surname: Alam
  fullname: Alam, Shoaib
– sequence: 3
  givenname: Anas
  surname: Shamsi
  fullname: Shamsi, Anas
– sequence: 4
  givenname: Mohd
  surname: Adnan
  fullname: Adnan, Mohd
– sequence: 5
  givenname: Abdelbaset Mohamed
  surname: Elasbali
  fullname: Elasbali, Abdelbaset Mohamed
– sequence: 6
  givenname: Waleed Abu
  surname: Al-Soud
  fullname: Al-Soud, Waleed Abu
– sequence: 7
  givenname: Mousa
  surname: Alreshidi
  fullname: Alreshidi, Mousa
– sequence: 8
  givenname: Yousef MohammedRabaa
  surname: Hawsawi
  fullname: Hawsawi, Yousef MohammedRabaa
– sequence: 9
  givenname: Anitha
  surname: Tippana
  fullname: Tippana, Anitha
– sequence: 10
  givenname: Visweswara Rao
  surname: Pasupuleti
  fullname: Pasupuleti, Visweswara Rao
– sequence: 11
  givenname: Md. Imtaiyaz
  surname: Hassan
  fullname: Hassan, Md. Imtaiyaz
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35402265$$D View this record in MEDLINE/PubMed
BookMark eNp1kk1v1DAQhi1UREvpnRPykUu2jp04MQckumrLSitAZZG4WRNnnE2Vjbe2A-y_x8u2qEXCB3-M533GGr8vydHoRiTkdc5mQtTq3LrRzDjjfFZLJSv-jJxwLopMFeL70aP9MTkL4ZalIUuWM_GCHIuySDpZnpDuAn6dX5gh43QOwUCLdBHoDXbTABFb2uxoXCO9vL66oV8grn_C7h1drdHDFqfYG7oC32Hsx446Sz-5Mfu6gWGgc0zTckrhOYwG_Svy3MIQ8Ox-PSXfri5X84_Z8vP1Yv5hmZmS1zEzsmYNBwUMVM6tKk1jRWmFYoLXpmYVYlHlzOSyRYOMS2SyydvUBWEbY2pxShYHbuvgVm99vwG_0w56_SfgfKfBp3cPqLFoy6pWLYjcFFwpsMDSobJQJV7RJNb7A2s7NRtsDY7Rw_AE-vRm7Ne6cz90rRSrqjwB3t4DvLubMES96YNJnYER3RQ0l4XipeQVS6lvHtf6W-Thp1KCPCQY70LwaLXpI8Te7Uv3g86Z3rtC712h967QB1ckIftH-MD-r-Q3TWC5lA
CitedBy_id crossref_primary_10_1016_j_phytochem_2024_114272
crossref_primary_10_1016_j_toxicon_2024_107673
crossref_primary_10_1021_acsomega_3c02424
crossref_primary_10_3389_fvets_2024_1413523
crossref_primary_10_3390_antiox14020237
crossref_primary_10_1016_j_prp_2024_155792
crossref_primary_10_1002_jcb_30468
crossref_primary_10_3390_ijms25116246
crossref_primary_10_1021_envhealth_4c00200
crossref_primary_10_1016_j_pep_2024_106649
crossref_primary_10_3390_molecules27238263
crossref_primary_10_2174_1573409920666230831144716
crossref_primary_10_1007_s00210_024_03375_2
crossref_primary_10_3389_fcell_2024_1462339
crossref_primary_10_1002_1878_0261_13764
crossref_primary_10_1016_j_jep_2022_115469
crossref_primary_10_3390_jox15020045
crossref_primary_10_1016_j_jff_2023_105845
crossref_primary_10_1016_j_jim_2023_113456
crossref_primary_10_1016_j_jpba_2024_116077
crossref_primary_10_1021_acsmedchemlett_2c00353
crossref_primary_10_3389_fbioe_2022_1068699
crossref_primary_10_1080_15384047_2024_2392902
crossref_primary_10_1080_13880209_2024_2331060
crossref_primary_10_1038_s41598_023_47558_y
crossref_primary_10_3390_molecules27134181
crossref_primary_10_1186_s43556_024_00240_9
crossref_primary_10_1111_bph_16141
crossref_primary_10_1186_s12645_024_00252_8
crossref_primary_10_3389_fonc_2022_985363
crossref_primary_10_1016_j_toxicon_2024_108149
crossref_primary_10_1021_acsomega_2c07766
crossref_primary_10_3389_fphar_2023_1291920
crossref_primary_10_1016_j_microc_2025_113317
crossref_primary_10_1155_2022_9985160
crossref_primary_10_1016_j_tice_2024_102701
crossref_primary_10_3389_fonc_2022_945102
crossref_primary_10_1080_10406638_2023_2273878
crossref_primary_10_1016_j_arres_2023_100085
crossref_primary_10_1186_s13020_025_01061_w
crossref_primary_10_1177_1934578X251328289
crossref_primary_10_53433_yyufbed_1220984
crossref_primary_10_1039_D4RA03157A
crossref_primary_10_1186_s12935_024_03391_5
crossref_primary_10_1016_j_ejphar_2025_177494
crossref_primary_10_3390_ijms26031078
crossref_primary_10_3390_receptors3030016
crossref_primary_10_1016_j_biopha_2023_114710
crossref_primary_10_3390_molecules28134947
crossref_primary_10_1016_j_heliyon_2024_e36816
crossref_primary_10_1016_j_psj_2024_103430
crossref_primary_10_1016_j_phytochem_2022_113213
crossref_primary_10_3390_ijms242015208
crossref_primary_10_1186_s12610_025_00254_5
crossref_primary_10_1615_JEnvironPatholToxicolOncol_2024051317
crossref_primary_10_3389_fphar_2023_1238639
Cites_doi 10.1186/1471-2407-10-302
10.1016/j.ejphar.2006.11.014
10.1016/j.taap.2006.11.024
10.1210/en.2015-1964
10.1056/NEJMoa0810699
10.1016/j.canlet.2014.03.001
10.1093/jnci/djh217
10.3390/ph14040369
10.1200/JCO.2009.24.3030
10.1016/j.jnutbio.2010.09.005
10.1016/j.neo.2015.07.003
10.1073/pnas.1404399111
10.1186/bcr1323
10.1371/journal.pmed.0040316
10.1159/000467897
10.3390/cancers13081898
10.1124/jpet.112.191536
10.1186/1471-2407-12-280
10.1186/1477-3163-5-10
10.1158/1078-0432.CCR-15-2266
10.1016/S0304-3835(02)00378-6
10.1016/j.gene.2005.10.018
10.1158/1940-6207.CAPR-09-0063
10.1023/A:1022807207948
10.3892/ijo.2013.1895
10.1158/1535-7163.MCT-16-0342
10.1517/14728214.2010.497754
10.1371/journal.pone.0179672
10.1073/pnas.91.20.9238
10.1016/j.cellbi.2007.04.009
10.1081/DCT-120020404
10.1200/JCO.2004.08.001
10.5732/cjc.011.10404
10.1126/science.1099314
10.1093/abbs/gmq107
10.1001/jama.299.8.937
10.1056/NEJMoa1502309
10.1016/S0014-4827(03)00264-7
10.1016/j.canlet.2014.06.010
10.1016/j.bbrc.2016.11.038
10.18632/oncotarget.24015
10.3892/or.2015.3886
10.1002/jcb.30162
10.3978/j.issn.2218-6751.2014.08.04
10.18632/oncotarget.24744
10.1200/JCO.2003.10.038
10.1016/j.oraloncology.2012.06.016
10.1083/jcb.139.5.1281
10.1200/JCO.2002.10.112
10.1158/2159-8290.CD-13-0609
10.18632/oncotarget.24814
10.1146/annurev.physiol.60.1.533
10.1590/S0100-879X2006005000108
10.1111/j.1753-0407.2010.00091.x
10.3892/or.2014.3223
10.1158/1535-7163.MCT-08-1078
10.1007/s00204-020-02816-0
10.1093/carcin/bgm172
10.1016/S0960-9822(06)00410-6
10.1158/0008-5472.CAN-12-1365
10.4103/0973-3930.41980
10.1038/335440a0
10.1110/ps.052045306
10.1200/JCO.2010.33.4235
10.1158/0008-5472.CAN-04-4570
10.1158/1078-0432.CCR-08-1575
10.4161/cbt.9.6.11392
10.1056/NEJMoa050753
10.1186/1750-2187-5-14
10.1016/j.taap.2006.11.013
10.1093/jn/133.7.2417S
10.1158/1078-0432.CCR-11-3090
10.1038/nrc969
10.1097/CAD.0000000000000548
10.3390/ijms221910442
10.1159/000007258
10.1002/jcb.20678
10.1200/JCO.2004.07.215
10.1093/ajcn/71.6.1698S
10.1158/1078-0432.CCR-12-1818
10.1016/j.advenzreg.2006.01.004
10.1634/theoncologist.8-4-303
10.1186/s12935-019-0981-0
10.1128/mcb.9.2.701-710.1989
10.1080/01635581.2010.509832
10.1016/j.oraloncology.2006.02.009
10.1038/nm.3048
10.3390/biom9050174
10.31033/ijrasb.7.6.14
10.18632/oncotarget.13141
10.1182/blood-2018-08-868752
10.1182/blood.V124.21.3645.3645
10.1054/bjoc.2000.1201
10.1200/JCO.2008.18.7658
10.1002/ijc.21205
10.1016/S0959-8049(01)00233-7
10.1021/acs.jnatprod.5b01055
10.1080/01635589109514142
10.1093/annonc/mdv072
10.1007/s13277-016-5362-x
10.1186/s13578-020-00397-0
10.1038/sj.cdd.4401975
10.2337/db11-1464
10.1186/s13045-019-0731-8
10.1097/00001813-200201000-00011
10.4021/jem12e
10.2741/2691
10.1002/(SICI)1097-0142(19990201)85:3<591::AID-CNCR9>3.0.CO;2-F
10.1158/0008-5472.CAN-07-5836
10.1021/jf204362n
10.1200/JCO.2010.31.6208
10.1038/sj.bjc.6602647
10.1126/science.1059108
10.1586/17476348.2016.1115349
10.4161/cc.5.18.3277
10.1016/j.ccr.2013.06.002
10.1016/j.ccr.2005.06.012
10.3892/or.2017.5766
10.18632/oncotarget.19411
10.1016/j.pharmthera.2004.01.002
10.1186/1756-9966-29-87
10.1136/jcp.2005.031351
10.1016/j.lungcan.2017.02.020
10.1038/modpathol.3801018
10.1142/S2575900018500131
10.1378/chest.12-2345
10.18632/oncotarget.186
10.3390/molecules25143146
10.1159/000354402
10.1038/nature03579
10.1248/bpb.b12-01004
10.1089/rej.2007.0645
10.1158/2159-8290.CD-12-0103
10.1677/erc.1.00986
10.1158/0008-5472.CAN-08-4235
10.1136/mp.56.4.205
10.1038/sj.bjc.6601095
10.1016/S0378-8741(02)00324-0
10.1200/JCO.2015.66.0084
10.1016/j.cell.2012.08.029
10.1016/S0027-5107(02)00336-6
10.1039/C8FO01397G
10.1056/NEJMra1703413
10.1155/2012/521215
10.1158/1078-0432.CCR-04-1289
10.1016/j.biopha.2022.112658
10.18632/oncotarget.2336
10.1038/sj.bjc.6600182
10.3892/etm.2015.2912
10.1080/09537100801915142
10.1016/S1470-2045(16)30146-2
10.18632/oncotarget.20311
10.1200/JCO.2011.34.7898
10.1200/jco.2011.29.15_suppl.cra7506
10.1634/theoncologist.12-1-90
10.3322/caac.21262
10.1371/journal.pone.0052483
10.1053/j.seminoncol.2015.05.007
10.18632/oncotarget.24301
10.1093/jnci/dji055
10.1074/jbc.M111.304022
10.14348/molcells.2015.0037
10.1038/348334a0
10.1016/j.ccr.2006.08.027
10.1038/nature07423
10.1073/pnas.0405220101
10.1016/j.ceb.2005.10.001
10.1111/j.0959-9673.2005.00448.x
10.1016/j.jcma.2013.01.010
10.1002/ptr.2766
10.1016/j.bbamcr.2017.06.017
10.1371/journal.pmed.0040294
10.1158/0008-5472.CAN-04-1443
10.1158/1078-0432.CCR-13-0657
10.1128/MCB.19.2.1313
10.1158/0008-5472.CAN-09-3565
10.1016/j.jhep.2004.08.024
10.1207/S15327914NC4502_09
10.1126/science.6093263
10.1186/s13045-015-0224-3
10.1016/j.lungcan.2018.07.013
10.1016/j.abb.2010.06.013
10.1080/15384047.2015.1108485
10.3892/ol.2018.8198
10.3349/ymj.2022.63.1.16
10.3945/jn.108.096271
10.1007/s10495-014-1030-z
10.1016/0092-8674(93)90509-O
10.1038/369321a0
10.1038/nrc2947
10.1016/S1470-2045(11)70184-X
10.1111/jcmm.14086
10.1038/35052073
10.3390/pharmaceutics12080761
10.1007/s00432-021-03593-8
10.1056/NEJMoa040938
10.1038/s41388-019-0887-2
10.4103/0973-7847.194044
10.1158/1078-0432.CCR-08-1757
10.1111/jcmm.14455
10.1158/2159-8290.CD-14-1467
10.1016/j.jnutbio.2007.11.003
10.3892/ijo.2013.1920
10.1016/j.foodchem.2022.132135
10.1038/s41467-021-21258-5
10.1007/s00280-014-2530-9
10.1016/j.crvi.2007.11.001
10.1016/j.drudis.2015.11.008
10.1155/2021/6612365
10.1016/S0955-2863(01)00219-4
10.3892/mmr.2012.845
10.1158/1535-7163.465.3.4
10.1158/1078-0432.CCR-06-3043
10.1371/journal.pmed.0040315
10.3390/molecules26216677
10.1016/j.cbi.2010.01.025
10.1007/s13402-017-0358-0
10.1101/cshperspect.a020768
10.3892/etm.2010.144
10.1038/nm0302-274
10.1186/1471-2407-6-224
10.1158/1078-0432.CCR-17-1606
10.4103/0973-1296.182154
10.1007/s00432-005-0005-4
10.1007/s00204-014-1300-0
10.1016/j.jep.2009.11.001
10.1002/ijc.23610
10.1097/00008469-199910000-00009
10.7150/ijms.4609
10.1038/nrm2308
10.1016/S0092-8674(04)00046-7
10.1038/sj.onc.1204087
10.1016/j.cgh.2006.03.020
10.1016/j.bbrc.2007.06.030
10.1002/ijc.21809
10.1016/0304-3835(92)90087-C
10.1016/j.ijbiomac.2021.06.022
10.1016/0308-8146(92)90153-S
10.3390/biom11091271
10.1097/01.cad.0000203381.99490.ab
10.1124/mol.108.052969
10.1016/S0024-3205(00)01020-1
10.1177/1934578X20912864
10.1007/s11010-013-1772-x
10.1038/nrc2088
10.1101/cshperspect.a008722
10.1016/S1470-2045(16)00077-2
10.1093/carcin/23.8.1307
10.1016/j.mrfmmm.2010.10.007
10.1111/gtc.12022
10.1016/s0254-6272(17)30008-0
10.1158/0008-5472.379.65.2
10.1080/14786419.2017.1385015
10.1007/s13277-014-2628-z
10.1074/jbc.M305063200
10.1016/j.fct.2010.05.072
10.1371/journal.pone.0022934
10.3892/or.2016.4587
10.1016/j.bcp.2005.02.022
10.1007/s12253-013-9695-0
10.1146/annurev.pharmtox.42.082101.154309
10.18632/oncotarget.10130
10.1016/0169-5002(96)00568-5
10.1158/1078-0432.CCR-09-0109
10.2741/2435
10.3904/kjim.1999.14.1.42
10.1016/S0014-827X(01)01111-9
10.12659/MSM.920537
10.1038/sj.onc.1208377
10.1158/2159-8290.CD-15-0285
10.1016/j.jtho.2020.11.028
10.18632/oncotarget.13307
10.1016/S0002-8223(96)00273-8
10.1002/j.1460-2075.1988.tb02791.x
10.1002/hed.25471
10.1073/pnas.041619798
10.1093/bfgp/elab038
10.1155/2014/943648
10.1158/1078-0432.CCR-04-0551
10.1038/nrclinonc.2010.97
10.1080/14786419.2010.533669
10.1007/s00280-012-2063-z
10.1038/sj.cdd.4402081
10.1016/j.ctrv.2013.06.002
10.1371/journal.pmed.0020017
10.1038/385353a0
10.1093/carcin/22.2.287
10.1016/j.emc.2009.02.001
10.1016/j.drudis.2020.07.019
10.1056/NEJMoa1513257
10.1007/s00784-017-2074-6
10.1038/s41598-020-62136-2
10.1158/1535-7163.MCT-08-1118
10.1111/j.1742-7843.2008.00260.x
10.1158/1078-0432.CCR-04-1036
10.3389/fonc.2022.860508
10.1309/JQ2X3RV3L8F9TGYW
10.1093/hmg/10.21.2329
10.1016/S0731-7085(98)00300-8
10.1038/onc.2008.259
10.1093/jjco/hyn089
10.3389/fphar.2022.845871
10.1126/science.1141478
10.3892/or.2013.2933
10.18632/oncotarget.5523
10.1200/JCO.2006.07.3585
10.3892/ijo.31.4.705
10.2174/187152009787313855
10.1016/j.oraloncology.2008.05.021
10.1007/s12199-013-0336-8
10.1001/jama.290.16.2149
10.1097/CAD.0b013e3283330590
10.1155/2013/925804
10.1158/0008-5472.CAN-07-5031
10.1002/jcp.27710
10.1200/JCO.2015.63.4600
10.3390/molecules26051315
10.1002/ptr.1309
10.1016/j.fct.2013.12.015
10.1093/jn/138.4.753
10.1186/1475-2867-10-22
10.1182/blood-2006-08-043257
10.1056/NEJMoa0909530
10.1200/jco.2005.23.16_suppl.7035
10.1006/bbrc.1998.0139
10.3892/or.2016.5019
10.3390/ijms222212162
10.1182/blood-2014-05-574566
10.1016/j.lfs.2021.119705
ContentType Journal Article
Copyright Copyright © 2022 Alam, Alam, Shamsi, Adnan, Elasbali, Al-Soud, Alreshidi, Hawsawi, Tippana, Pasupuleti and Hassan.
Copyright © 2022 Alam, Alam, Shamsi, Adnan, Elasbali, Al-Soud, Alreshidi, Hawsawi, Tippana, Pasupuleti and Hassan 2022 Alam, Alam, Shamsi, Adnan, Elasbali, Al-Soud, Alreshidi, Hawsawi, Tippana, Pasupuleti and Hassan
Copyright_xml – notice: Copyright © 2022 Alam, Alam, Shamsi, Adnan, Elasbali, Al-Soud, Alreshidi, Hawsawi, Tippana, Pasupuleti and Hassan.
– notice: Copyright © 2022 Alam, Alam, Shamsi, Adnan, Elasbali, Al-Soud, Alreshidi, Hawsawi, Tippana, Pasupuleti and Hassan 2022 Alam, Alam, Shamsi, Adnan, Elasbali, Al-Soud, Alreshidi, Hawsawi, Tippana, Pasupuleti and Hassan
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fonc.2022.869672
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed

CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2234-943X
ExternalDocumentID oai_doaj_org_article_e4d5789da31c4299afa0da37fa72024b
PMC8990771
35402265
10_3389_fonc_2022_869672
Genre Journal Article
Review
GrantInformation_xml – fundername: ;
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EJD
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c528t-c680b2a9a0a912f95cbf35f390328c807ee4710c16dece026e06b1d2023fbcc83
IEDL.DBID M48
ISSN 2234-943X
IngestDate Wed Aug 27 01:31:32 EDT 2025
Thu Aug 21 18:29:25 EDT 2025
Fri Jul 11 05:03:07 EDT 2025
Mon Jul 21 06:06:11 EDT 2025
Thu Apr 24 23:02:18 EDT 2025
Tue Jul 01 02:46:31 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords B cell lymphoma 2
Bax
targeted therapy
apoptosis
signaling
NSCLC
Language English
License Copyright © 2022 Alam, Alam, Shamsi, Adnan, Elasbali, Al-Soud, Alreshidi, Hawsawi, Tippana, Pasupuleti and Hassan.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c528t-c680b2a9a0a912f95cbf35f390328c807ee4710c16dece026e06b1d2023fbcc83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Rajesh Sinha, University of Alabama at Birmingham, United States; Aditya Padhi, RIKEN Yokohama, Japan; Somasish Dastidar, Manipal Academy of Higher Education, India
Edited by: Mohd Wasim Nasser, University of Nebraska Medical Center, United States
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fonc.2022.869672
PMID 35402265
PQID 2649256270
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_e4d5789da31c4299afa0da37fa72024b
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8990771
proquest_miscellaneous_2649256270
pubmed_primary_35402265
crossref_citationtrail_10_3389_fonc_2022_869672
crossref_primary_10_3389_fonc_2022_869672
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-03-25
PublicationDateYYYYMMDD 2022-03-25
PublicationDate_xml – month: 03
  year: 2022
  text: 2022-03-25
  day: 25
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in oncology
PublicationTitleAlternate Front Oncol
PublicationYear 2022
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Fukuoka (B161) 2003; 21
Wang (B169) 2018; 9
Otake (B82) 2007; 109
Ciardiello (B132) 2000; 6
Zhang (B84) 2006; 6
Milligan (B205) 2009; 15
Pramanik (B134) 2018; 41
Lambert (B193) 2010; 501
Banerjee (B255) 2009; 69
Saxena (B47) 2002; 187
Chen (B309) 2005; 69
Newman (B135) 2016; 79
Sadava (B187) 2007; 360
Ding (B102) 2008; 455
Padhye (B261) 2008; 6
Tsujimoto (B61) 1989; 4
Wilhelm (B130) 2004; 64
Luo (B212) 2018; 9
Zhang (B19) 2014; 5
Sato (B38) 1994; 91
Yang (B254) 2015; 36
Tsujimoto (B57) 1984; 226
Laudanski (B78) 1999; 46
Alam (B198) 2021; 22
Chen (B9) 2013; 76
Hashemzaei (B293) 2017; 38
Lynch (B95) 2004; 350
Sakalar (B278) 2013; 383
Ercan (B14) 2012; 2
Yamamoto (B210) 2007; 224
Sirotnak (B340) 2000; 6
Rahmani (B235) 2013; 73
Alam (B48) 2019; 41
Lu (B138) 2018; 1
Chung (B209) 2001; 68
Huang (B228) 2000; 19
Callaghan (B90) 1993; 8
Vaillant (B151) 2013; 24
Oltersdorf (B222) 2005; 435
Vafadar (B294) 2020; 10
Raffo (B87) 1995; 55
Chun (B301) 2008; 138
Lupo (B318) 2019; 23
Ricciuti (B110) 2016; 10
Li (B200) 2002; 23
Xia (B232) 2017; 8
Peirs (B331) 2014; 124
Alam (B40) 2021; 22
Ono (B170) 2004; 3
Ma (B213) 2014; 31
Vogler (B148) 2014; 2014
Samali (B272) 1999; 255
Kitagawa (B180) 2013; 18
Ciardiello (B355) 1999; 5
Sequist (B112) 2007; 25
Najmi (B246) 2008; 28
Koh (B218) 2011; 22
Chen (B155) 2002; 1
Cory (B221) 2005; 8
El-Ghany (B286) 2009; 3
Han (B143) 2021; 2021
Cragg (B171) 2007; 4
DiNardo (B332) 2019; 133
Klanova (B337) 2014; 124
Camisasca (B54) 2009; 45
Ji (B118) 2006; 5
Willis (B63) 2005; 17
Johnson (B13) 2012; 31
Khader (B259) 2010; 127
Zhang (B236) 2016; 11
Dou (B140) 2018; 9
Zhang (B37) 2001; 10
Aharoni-Simon (B81) 2016; 157
Robaszkiewicz (B291) 2007; 31
Bourgou (B258) 2008; 331
Brehmer (B179) 2005; 65
Almatroodi (B211) 2020; 25
Hardwick (B70) 2013; 5
Yang (B183) 2007; 224
Zhang (B142) 2017; 12
Li (B194) 2016; 35
Lin (B195) 2012; 60
Meng (B192) 2008; 11
Yarden (B91) 2001; 2
Masuda (B146) 2001; 7
Cufer (B164) 2006; 17
Han (B307) 2016; 12
Yang (B186) 2002; 42
Kundu (B284) 2014; 32
Sabetkar (B191) 2008; 19
Jeong (B50) 2008; 38
Hoffmann (B158) 2002; 13
Ladanyi (B111) 2008; 21
Aldebasi (B266) 2013; 6
Normanno (B11) 2006; 366
Gong (B233) 2007; 4
Grandis (B92) 2004; 102
Festuccia (B168) 2005; 12
Wei (B41) 2001; 292
Pećina-Šlaus (B36) 2010; 10
Liu (B356) 2000; 82
Almajali (B253) 2021; 14
Tagscherer (B230) 2008; 27
Premkumar (B234) 2012; 341
Petros (B66) 2001; 98
Massarelli (B129) 2007; 13
Lee (B298) 2015; 89
Randhawa (B262) 2008; 20
Hagen (B196) 2013; 43
Kiprianova (B242) 2015; 17
Feng (B77) 2018; 15
Höpfner (B174) 2004; 41
Tse (B150) 2008; 68
Farah (B260) 2003; 39
Gupta (B30) 2021; 13
Alhakamy (B280) 2020; 12
Baby (B317) 2018; 32
Reck (B103) 2017; 377
Viktorsson (B52) 2003; 289
Nagi (B274) 2009; 23
Vijayababu (B312) 2006; 5
Alam (B53) 2017; 21
Nix (B56) 2005; 92
Wang (B219) 2019; 19
McCubrey (B105) 2006; 46
Abourehab (B98) 2021; 26
Yang (B295) 2015; 33
Pan (B325) 2014; 4
Kris (B162) 2003; 290
Deng (B139) 2017; 41
Alam (B99) 2022; 13
Duo (B311) 2012; 5
Liu (B334) 2020; 94
Badary (B270) 2003; 26
Xu (B357) 2010; 10
Shibata (B76) 2004; 24
Zhou (B109) 2014; 351
Hirata (B178) 2002; 62
Ikegaki (B67) 1994; 54
Mukhtar (B184) 2000; 71
Mathur (B250) 2011; 1
Laimer (B115) 2007; 43
Hann (B229) 2008; 68
Cang (B328) 2015; 8
Cosulich (B33) 1997; 7
El-Mowafy (B189) 2011; 25
Nagi (B271) 2010; 48
Yang (B29) 2020; 15
Emi (B17) 2005; 7
Fathy (B276) 2013; 18
Gibson (B85) 2000; 6
Banerjee (B247) 2010; 62
Nakajima (B18) 2016; 17
Zhang (B300) 2015; 38
Ariyama (B172) 2006; 97
Shaib (B117) 2012; 2012
Shajahan (B240) 2012; 287
Cappuzzo (B173) 2004; 96
Zhou (B342) 2011; 12
Zhao (B106) 2017; 108
Warren (B304) 2009; 139
Frampton (B352) 2015; 5
Adhami (B207) 2003; 133
Salim (B257) 2003; 45
Gulati (B322) 2006; 26
Salomi (B268) 1991
Downward (B108) 2003; 3
Sinicrope (B157) 2004; 10
El-Aziz (B256) 2005; 86
Imielinski (B7) 2012; 150
Paik (B354) 2015; 5
Wolter (B31) 1997; 139
El-Mahdy (B287) 2005; 117
Hockenbery (B58) 1990; 348
Seto (B60) 1988; 7
Kaefer (B226) 2014; 74
Lemmon (B338) 2014; 6
Remon (B20) 2014; 40
Pao (B96) 2004; 101
Jebahi (B238) 2014; 348
Sinkevicius (B3) 2014; 111
David (B297) 2016; 10
Luciani (B71) 2013; 62
Ashimori (B152) 2009; 8
Zhu (B72) 2006; 59
Kazandjian (B177) 2016; 22
Gandhi (B224) 2011; 29
Niu (B314) 2011; 43
Shepherd (B167) 2005; 353
Chang (B292) 2017; 1864
Cardarella (B348) 2013; 19
García-Mediavilla (B302) 2007; 557
Wei (B199) 2018; 9
Douillard (B343) 2010; 28
Yan (B137) 2018; 11
Soh (B93) 1999; 19
Steinmetz (B251) 1996; 96
Baselga (B131) 2001; 37
Li (B216) 2013; 6
Shin (B239) 2015; 6
Kidd (B32) 1998; 60
Samarghandian (B281) 2019; 234
Salomi (B269) 1992; 63
Alam (B97) 2022; 132135
Wakeling (B175) 2002; 62
Jafri (B252) 2010; 29
Giaccone (B165) 2004; 22
Liu (B64) 2016; 21
Begum (B296) 2002; 13
Guardia (B303) 2001; 56
Minn (B68) 1997; 385
Chen-Levy (B59) 1989; 9
Zhang (B333) 2007; 14
Arafa (B267) 2011; 706
Planchard (B350) 2016; 17
Ciardiello (B339) 2000; 6
Souers (B329) 2013; 19
Huat (B273) 2003; 245
Hu (B358) 2014; 19
Rudin (B227) 2012; 18
Kashyap (B319) 2019; 9
Hu (B74) 2004; 10
Ranson (B160) 2002; 20
Lamson (B290) 2000; 5
Alam (B15) 2020; 7
Lin (B206) 2012; 60
Kaiser (B79) 1996; 15
Alberg (B2) 2013; 143
Maemondo (B120) 2010; 362
Guy (B335) 2021; 147
Lim (B49) 2006
Kuhar (B315) 2006; 26
Herbst (B166) 2004; 22
Planchard (B351) 2016; 17
Wargo (B119) 2015; 42
Tang (B185) 2010; 5
Singh (B283) 2018
Hyman (B349) 2015; 373
Jackel (B83) 1999; 85
Park (B285) 2016; 36
Petigny-Lechartier (B237) 2017; 16
LeBlanc (B44) 2002; 8
Ferrer (B125) 2018; 124
Riaz (B204) 2017; 28
Inoue (B123) 2009; 27
Cohen (B176) 2003; 8
Fouda (B277) 2008; 103
Choi (B73) 2005; 65
Hauck (B225) 2009; 8
Leone (B145) 2003; 63
Lee (B89) 2006; 15
Amin (B208) 2009; 2
Torre (B1) 2015; 65
Casara (B159) 2018; 9
Modjtahedi (B116) 2009; 20
Katiyar (B190) 2001; 22
Mese (B86) 2000; 46
Wang (B241) 2012; 7
Roberts (B326) 2016; 374
Lochmann (B330) 2018; 24
Ali (B282) 2022; 147
Ali (B100) 2021
Lambert (B182) 2003
Wang (B313) 2016; 36
Danial (B62) 2004; 116
Kris (B10) 2011; 29
Zhong (B21) 2017; 8
Wheeler (B346) 2010; 7
Ghosheh (B245) 1999; 19
Zhang (B128) 2019; 12
Youle (B35) 2008; 9
Nor (B88) 2001; 61
Pao (B101) 2005; 2
Van Delft (B231) 2006; 10
Awad (B353) 2016; 34
Youn (B299) 2013; 36
Reed (B65) 2006; 13
Paez (B344) 2004; 304
Sequist (B24) 2007; 12
Abrahm (B4) 2008; 299
Costa (B25) 2007; 4
Williams (B341) 2002; 86
Ait Mbarek (B263) 2007; 40
Yin (B69) 1994; 369
Zhong (B107) 2010; 184
Zou (B28) 2013; 42
Adams (B141) 2010; 70
Zhu (B214) 2017; 482
Shigematsu (B113) 2005; 97
Rabinowits (B8) 2012; 48
Chen (B42) 2007; 28
Almatroodi (B321) 2021; 26
Chen (B220) 2020; 10
Mok (B121) 2009; 361
Al-Jassir (B244) 1992; 45
Roberts (B149) 2012; 30
Kundu (B248) 2014; 65
Lee (B223) 2022; 63
Cruz–Correa (B306) 2006; 4
Lu (B27) 2019; 23
Mitsudomi (B104) 2014; 3
Engelman (B359) 2007; 316
Martin (B75) 2003; 89
Wang (B153) 2008; 123
Blumenschein (B124) 2015; 26
Alam (B144) 2022; 123
Pao (B23) 2010; 10
Thiagarajan (B336) 2016; 7
Alam (B16) 2021; 280
Tang (B197) 2007; 31
Relat (B217) 2012; 12
Sun (B5) 2009; 27
Blumenschein (B122) 2013; 19
Antonicelli (B347) 2013; 10
Ali (B279) 2003; 17
Shankar (B202) 2007; 12
Dong (B320) 2020; 26
Fung (B12) 2012; 15
Hirpara (B289) 2009; 9
Pradhan (B324) 2010; 1
Afrose (B288) 2020; 25
Xiao (B305) 2011; 6
Moshynska (B43) 2003; 56
Vijayababu (B310) 2005; 131
Lee (B136) 2013; 2013
Badary (B264) 1999; 8
Sharma (B26) 2007; 7
Leibowitz (B34) 2010; 9
Papadimitrakopoulou (B126) 2016; 34
Li (B147) 2009; 75
Shankar (B201) 2008; 13
Huang (B156) 2009; 15
Abdelmeguid (B275) 2010; 2
Huang (B316) 2021; 11
Raoof (B22) 2019; 38
Nagasaka (B127) 2021; 16
Cufer (B163) 2005; 23
Suganuma (B188) 2006; 119
He (B215) 2013; 71
Kancha (B181) 2009; 15
Han (B51) 1999; 14
Manoochehri (B55) 2014; 20
Pratheeshkumar (B308) 2017; 8
Kaefer (B249) 2008; 19
Moshynska (B46) 2005; 24
Vaux (B80) 1988; 335
Oliver (B154) 2004; 10
El-Abhar (B265) 2003; 84
Spencer (B323) 2003; 278
Fukuoka (B345) 2011; 29
Oltvai (B39) 1993; 74
Mukherjee (B327) 2016; 7
Hmza (B243) 2013; 4
Alam (B94) 2021; 183
Pramanik (B114) 2016; 37
Alam (B133) 2022; 12
Zhao (B203) 2021; 12
Miquel (B45) 2005; 123
Zhang (B6) 2010; 1
References_xml – volume: 10
  start-page: 1
  year: 2010
  ident: B357
  article-title: Expression of Growth Factor Receptors and Targeting of EGFR in Cholangiocarcinoma Cell Lines
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-10-302
– volume: 557
  year: 2007
  ident: B302
  article-title: The Anti-Inflammatory Flavones Quercetin and Kaempferol Cause Inhibition of Inducible Nitric Oxide Synthase, Cyclooxygenase-2 and Reactive C-Protein, and Down-Regulation of the Nuclear Factor kappaB Pathway in Chang Liver Cells
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2006.11.014
– volume: 224
  year: 2007
  ident: B183
  article-title: Tea and Cancer Prevention: Molecular Mechanisms and Human Relevance
  publication-title: Toxicol Appl Pharmacol
  doi: 10.1016/j.taap.2006.11.024
– volume: 157
  year: 2016
  ident: B81
  article-title: Bcl-2 Regulates Reactive Oxygen Species Signaling and a Redox-Sensitive Mitochondrial Proton Leak in Mouse Pancreatic β-Cells
  publication-title: Endocrinology
  doi: 10.1210/en.2015-1964
– volume: 361
  year: 2009
  ident: B121
  article-title: Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0810699
– volume: 348
  start-page: 38
  year: 2014
  ident: B238
  article-title: PI3K/mTOR Dual Inhibitor NVP-BEZ235 Decreases Mcl-1 Expression and Sensitizes Ovarian Carcinoma Cells to Bcl-xL-Targeting Strategies, Provided That Bim Expression is Induced
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2014.03.001
– volume: 96
  year: 2004
  ident: B173
  article-title: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced non–Small-Cell Lung Cancer
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djh217
– volume: 14
  start-page: 369
  year: 2021
  ident: B253
  article-title: Thymoquinone, as a Novel Therapeutic Candidate of Cancers
  publication-title: Pharmaceuticals
  doi: 10.3390/ph14040369
– volume: 28
  year: 2010
  ident: B343
  article-title: Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated non-Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.24.3030
– volume: 22
  year: 2011
  ident: B218
  article-title: Green Tea (–)-Epigallocatechin-3-Gallate Inhibits HGF-Induced Progression in Oral Cavity Cancer Through Suppression of HGF/c-Met
  publication-title: J Nutr Biochem
  doi: 10.1016/j.jnutbio.2010.09.005
– volume: 17
  year: 2015
  ident: B242
  article-title: Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner
  publication-title: Neoplasia
  doi: 10.1016/j.neo.2015.07.003
– volume: 111
  year: 2014
  ident: B3
  article-title: Neurotrophin Receptor TrkB Promotes Lung Adenocarcinoma Metastasis
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.1404399111
– volume: 7
  start-page: 1
  year: 2005
  ident: B17
  article-title: Targeted Therapy Against Bcl-2-Related Proteins in Breast Cancer Cells
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr1323
– volume: 4
  start-page: e316
  year: 2007
  ident: B171
  article-title: Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and can be Enhanced by BH3 Mimetics
  publication-title: PloS Med
  doi: 10.1371/journal.pmed.0040316
– volume: 41
  year: 2017
  ident: B139
  article-title: Effects of Glycyrrhizin in a Mouse Model of Lung Adenocarcinoma
  publication-title: Cell Physiol Biochem
  doi: 10.1159/000467897
– volume: 13
  start-page: 1898
  year: 2021
  ident: B30
  article-title: Targeting the Sphingosine Kinase/Sphingosine-1-Phosphate Signaling Axis in Drug Discovery for Cancer Therapy
  publication-title: Cancers
  doi: 10.3390/cancers13081898
– volume: 341
  year: 2012
  ident: B234
  article-title: ABT-737 Synergizes With Bortezomib to Induce Apoptosis, Mediated by Bid Cleavage, Bax Activation, and Mitochondrial Dysfunction in an Akt-Dependent Context in Malignant Human Glioma Cell Lines
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.112.191536
– year: 2006
  ident: B49
  article-title: Low Expression of Bax in non-Small Cell Lung Cancer: Predictor of Poor Disease-Free Survival in Adenocarcinoma Patients With Surgical Resection (AACR)
– volume: 12
  start-page: 1
  year: 2012
  ident: B217
  article-title: Different Fatty Acid Metabolism Effects of (–)-Epigallocatechin-3-Gallate and C75 in Adenocarcinoma Lung Cancer
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-12-280
– volume: 5
  start-page: 10
  year: 2006
  ident: B312
  article-title: Effects of Quercetin on Insulin-Like Growth Factors (IGFs) and Their Binding Protein-3 (IGFBP-3) Secretion and Induction of Apoptosis in Human Prostate Cancer Cells
  publication-title: J Carcinogene
  doi: 10.1186/1477-3163-5-10
– volume: 22
  year: 2016
  ident: B177
  article-title: FDA Approval of Gefitinib for the Treatment of Patients With Metastatic EGFR Mutation–Positive non–Small Cell Lung Cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-2266
– volume: 187
  start-page: 199
  year: 2002
  ident: B47
  article-title: Association of a Novel Single Nucleotide Polymorphism, G(-248)A, in the 5'-UTR of BAX Gene in Chronic Lymphocytic Leukemia With Disease Progression and Treatment Resistance
  publication-title: Cancer Lett
  doi: 10.1016/S0304-3835(02)00378-6
– volume: 366
  start-page: 2
  year: 2006
  ident: B11
  article-title: Epidermal Growth Factor Receptor (EGFR) Signaling in Cancer
  publication-title: Gene
  doi: 10.1016/j.gene.2005.10.018
– volume: 2
  year: 2009
  ident: B208
  article-title: Synergistic Growth Inhibition of Squamous Cell Carcinoma of the Head and Neck by Erlotinib and Epigallocatechin-3-Gallate: The Role of P53-Dependent Inhibition of Nuclear factor-kappaB
  publication-title: Cancer Prev Res (Phila)
  doi: 10.1158/1940-6207.CAPR-09-0063
– volume: 245
  year: 2003
  ident: B273
  article-title: Intracellular Glutathione Depletion and Reactive Oxygen Species Generation are Important in α-Hederin-Induced Apoptosis of P388 Cells
  publication-title: Mol Cell Biochem
  doi: 10.1023/A:1022807207948
– volume: 5
  year: 1999
  ident: B355
  article-title: Antitumor Activity of Sequential Treatment With Topotecan and Anti-Epidermal Growth Factor Receptor Monoclonal Antibody C225
  publication-title: Clin Cancer Res
– volume: 42
  year: 2013
  ident: B28
  article-title: Knockdown of the Bcl-2 Gene Increases Sensitivity to EGFR Tyrosine Kinase Inhibitors in the H1975 Lung Cancer Cell Line Harboring T790M Mutation
  publication-title: Int J Oncol
  doi: 10.3892/ijo.2013.1895
– volume: 16
  year: 2017
  ident: B237
  article-title: The Mtorc1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] Ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-16-0342
– volume: 15
  year: 2012
  ident: B12
  article-title: Emerging Drugs to Treat Squamous Cell Carcinomas of the Head and Neck
  publication-title: Expert Opin Emerg Drugs
  doi: 10.1517/14728214.2010.497754
– volume: 12
  year: 2017
  ident: B142
  article-title: Dicumarol Inhibits PDK1 and Targets Multiple Malignant Behaviors of Ovarian Cancer Cells
  publication-title: PloS One
  doi: 10.1371/journal.pone.0179672
– volume: 91
  year: 1994
  ident: B38
  article-title: Interactions Among Members of the Bcl-2 Protein Family Analyzed With a Yeast Two-Hybrid System
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.91.20.9238
– volume: 31
  year: 2007
  ident: B291
  article-title: Antioxidative and Prooxidative Effects of Quercetin on A549 Cells
  publication-title: Cell Biol Int
  doi: 10.1016/j.cellbi.2007.04.009
– volume: 26
  start-page: 87
  year: 2003
  ident: B270
  article-title: Thymoquinone is a Potent Superoxide Anion Scavenger
  publication-title: Drug Chem Toxicol
  doi: 10.1081/DCT-120020404
– volume: 22
  year: 2004
  ident: B165
  article-title: Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced non-Small-Cell Lung Cancer: A Phase III Trial–INTACT 1
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2004.08.001
– volume: 31
  year: 2012
  ident: B13
  article-title: Targeting Proliferation and Survival Pathways in Head and Neck Cancer for Therapeutic Benefit
  publication-title: Chin J Cancer
  doi: 10.5732/cjc.011.10404
– volume: 304
  year: 2004
  ident: B344
  article-title: EGFR Mutations in Lung Cancer: Correlation With Clinical Response to Gefitinib Therapy
  publication-title: Science
  doi: 10.1126/science.1099314
– volume: 43
  year: 2011
  ident: B314
  article-title: Quercetin Induces Apoptosis by Activating Caspase-3 and Regulating Bcl-2 and Cyclooxygenase-2 Pathways in Human HL-60 Cells
  publication-title: Acta Biochim Biophys Sin
  doi: 10.1093/abbs/gmq107
– volume: 299
  year: 2008
  ident: B4
  article-title: Spinal Cord Compression in Patients With Advanced Metastatic Cancer:”All I Care About is Walking and Living My Life”
  publication-title: Jama
  doi: 10.1001/jama.299.8.937
– volume: 373
  year: 2015
  ident: B349
  article-title: Vemurafenib in Multiple Nonmelanoma Cancers With BRAF V600 Mutations
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa1502309
– volume: 289
  year: 2003
  ident: B52
  article-title: Defective Stress Kinase and Bak Activation in Response to Ionizing Radiation But Not Cisplatin in a Non-Small Cell Lung Carcinoma Cell Line
  publication-title: Exp Cell Res
  doi: 10.1016/S0014-4827(03)00264-7
– volume: 351
  year: 2014
  ident: B109
  article-title: MicroRNA-34a Overcomes HGF-Mediated Gefitinib Resistance in EGFR Mutant Lung Cancer Cells Partly by Targeting MET
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2014.06.010
– volume: 482
  start-page: 15
  year: 2017
  ident: B214
  article-title: Wnt/beta-Catenin Pathway Mediates (-)-Epigallocatechin-3-Gallate (EGCG) Inhibition of Lung Cancer Stem Cells
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2016.11.038
– volume: 9
  start-page: 20089
  year: 2018
  ident: B140
  article-title: Baicalein and Baicalin Inhibit Colon Cancer Using Two Distinct Fashions of Apoptosis and Senescence
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.24015
– volume: 33
  year: 2015
  ident: B295
  article-title: Quercetin in Prostate Cancer: Chemotherapeutic and Chemopreventive Effects, Mechanisms and Clinical Application Potential
  publication-title: Oncol Rep
  doi: 10.3892/or.2015.3886
– volume: 123
  year: 2022
  ident: B144
  article-title: Thymoquinone and Quercetin Induce Enhanced Apoptosis in non-Small Cell Lung Cancer in Combination Through the Bax/Bcl2 Cascade
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.30162
– volume: 3
  start-page: 205
  year: 2014
  ident: B104
  article-title: Molecular Epidemiology of Lung Cancer and Geographic Variations With Special Reference to EGFR Mutations
  publication-title: Trans Lung Cancer Res
  doi: 10.3978/j.issn.2218-6751.2014.08.04
– volume: 9
  year: 2018
  ident: B159
  article-title: S55746 is a Novel Orally Active BCL-2 Selective and Potent Inhibitor That Impairs Hematological Tumor Growth
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.24744
– volume: 6
  year: 2000
  ident: B85
  article-title: Induction of Apoptosis in Oral Cancer Cells by an Anti-Bcl-2 Ribozyme Delivered by an Adenovirus Vector
  publication-title: Clin Cancer Res
– volume: 21
  year: 2003
  ident: B161
  article-title: Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced non–Small-Cell Lung Cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2003.10.038
– volume: 48
  year: 2012
  ident: B8
  article-title: Overcoming Resistance to EGFR Inhibitor in Head and Neck Cancer: A Review of the Literature
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2012.06.016
– volume: 139
  year: 1997
  ident: B31
  article-title: Movement of Bax From the Cytosol to Mitochondria During Apoptosis
  publication-title: J Cell Biol
  doi: 10.1083/jcb.139.5.1281
– volume: 20
  year: 2002
  ident: B160
  article-title: ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2002.10.112
– volume: 4
  year: 2014
  ident: B325
  article-title: Selective BCL-2 Inhibition by ABT-199 Causes on-Target Cell Death in Acute Myeloid Leukemia
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-13-0609
– volume: 9
  start-page: 16533
  year: 2018
  ident: B169
  article-title: Molecular Mechanism of Action and Potential Biomarkers of Growth Inhibition of Synergistic Combination of Afatinib and Dasatinib Against Gefitinib-Resistant non-Small Cell Lung Cancer Cells
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.24814
– volume: 60
  year: 1998
  ident: B32
  article-title: Proteolytic Activities That Mediate Apoptosis
  publication-title: Annu Rev Physiol
  doi: 10.1146/annurev.physiol.60.1.533
– volume: 40
  year: 2007
  ident: B263
  article-title: Anti-Tumor Properties of Blackseed (Nigella Sativa L.) Extracts
  publication-title: Braz J Med Biol Res
  doi: 10.1590/S0100-879X2006005000108
– volume: 2
  year: 2010
  ident: B275
  article-title: Effects of Nigella Sativa and Thymoquinone on Biochemical and Subcellular Changes in Pancreatic β-Cells of Streptozotocin-Induced Diabetic Rats
  publication-title: J Diabetes
  doi: 10.1111/j.1753-0407.2010.00091.x
– volume: 32
  year: 2014
  ident: B284
  article-title: Thymoquinone Induces Apoptosis in Human Colon Cancer HCT116 Cells Through Inactivation of STAT3 by Blocking JAK2-And Src−mediated Phosphorylation of EGF Receptor Tyrosine Kinase
  publication-title: Oncol Rep
  doi: 10.3892/or.2014.3223
– volume: 8
  start-page: 893
  year: 2009
  ident: B152
  article-title: TW-37, a Small-Molecule Inhibitor of Bcl-2, Mediates S-Phase Cell Cycle Arrest and Suppresses Head and Neck Tumor Angiogenesis
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-08-1078
– volume: 94
  year: 2020
  ident: B334
  article-title: Synergistic Effects of Bcl-2 Inhibitors With AZD9291 on Overcoming the Acquired Resistance of AZD9291 in H1975 Cells
  publication-title: Arch Toxicol
  doi: 10.1007/s00204-020-02816-0
– volume: 28
  year: 2007
  ident: B42
  article-title: Single-Nucleotide Polymorphisms at the TP53-Binding or Responsive Promoter Regions of BAX and BCL2 Genes and Risk of Squamous Cell Carcinoma of the Head and Neck
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgm172
– volume: 7
  year: 1997
  ident: B33
  article-title: Regulation of Apoptosis by BH3 Domains in a Cell-Free System
  publication-title: Curr Biol
  doi: 10.1016/S0960-9822(06)00410-6
– volume: 46
  start-page: 25
  year: 1999
  ident: B78
  article-title: Expression of Bcl-2 Protein in non-Small Cell Lung Cancer: Correlation With Clinicopathology and Patient Survival
  publication-title: Neoplasma
– volume: 73
  year: 2013
  ident: B235
  article-title: Dual Inhibition of Bcl-2 and Bcl-xL Strikingly Enhances PI3K Inhibition-Induced Apoptosis in Human Myeloid Leukemia Cells Through a GSK3- and Bim-Dependent Mechanism
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-1365
– volume: 28
  start-page: 11
  year: 2008
  ident: B246
  article-title: Effect of Nigella Sativa Oil on Various Clinical and Biochemical Parameters of Insulin Resistance Syndrome
  publication-title: Int J Diabetes Develop Cntr
  doi: 10.4103/0973-3930.41980
– volume: 335
  year: 1988
  ident: B80
  article-title: Bcl-2 Gene Promotes Haemopoietic Cell Survival and Cooperates With C-Myc to Immortalize Pre-B Cells
  publication-title: Nature
  doi: 10.1038/335440a0
– volume: 15
  year: 2006
  ident: B89
  article-title: Structure and Dynamics of the Epidermal Growth Factor Receptor C-Terminal Phosphorylation Domain
  publication-title: Protein Sci
  doi: 10.1110/ps.052045306
– volume: 29
  year: 2011
  ident: B345
  article-title: Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced non–Small-Cell Lung Cancer in Asia (IPASS)
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.33.4235
– volume: 65
  year: 2005
  ident: B73
  article-title: Bcl-2 Promotes Invasion and Lung Metastasis by Inducing Matrix Metalloproteinase-2
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-04-4570
– volume: 6
  year: 2000
  ident: B132
  article-title: Antiangiogenic and Antitumor Activity of Anti-Epidermal Growth Factor Receptor C225 Monoclonal Antibody in Combination With Vascular Endothelial Growth Factor Antisense Oligonucleotide in Human GEO Colon Cancer Cells
  publication-title: Clin Cancer Res
– volume: 15
  year: 2009
  ident: B156
  article-title: BH3 Mimetic Obatoclax Enhances TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-08-1575
– volume: 9
  year: 2010
  ident: B34
  article-title: Mitochondrial Signaling in Cell Death via the Bcl-2 Family
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.9.6.11392
– volume: 353
  year: 2005
  ident: B167
  article-title: Erlotinib in Previously Treated non–Small-Cell Lung Cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa050753
– volume: 5
  start-page: 14
  year: 2010
  ident: B185
  article-title: The Dietary Bioflavonoid Quercetin Synergizes With Epigallocathechin Gallate (EGCG) to Inhibit Prostate Cancer Stem Cell Characteristics, Invasion, Migration and Epithelial-Mesenchymal Transition
  publication-title: J Mol Signal
  doi: 10.1186/1750-2187-5-14
– volume: 224
  year: 2007
  ident: B210
  article-title: EGCG-Targeted P57/KIP2 Reduces Tumorigenicity of Oral Carcinoma Cells: Role of C-Jun N-Terminal Kinase
  publication-title: Toxicol Appl Pharmacol
  doi: 10.1016/j.taap.2006.11.013
– volume: 133
  year: 2003
  ident: B207
  article-title: Molecular Targets for Green Tea in Prostate Cancer Prevention
  publication-title: J Nutr
  doi: 10.1093/jn/133.7.2417S
– volume: 18
  year: 2012
  ident: B227
  article-title: Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients With Relapsed Small Cell Lung Cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-11-3090
– volume: 3
  start-page: 11
  year: 2003
  ident: B108
  article-title: Targeting RAS Signalling Pathways in Cancer Therapy
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc969
– volume: 28
  year: 2017
  ident: B204
  article-title: Screening of Medicinal Plant Phytochemicals as Natural Antagonists of P53-MDM2 Interaction to Reactivate P53 Functioning
  publication-title: Anticancer Drugs
  doi: 10.1097/CAD.0000000000000548
– volume: 22
  start-page: 10442
  year: 2021
  ident: B40
  article-title: B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms221910442
– volume: 46
  start-page: 69
  year: 2000
  ident: B86
  article-title: Regulation of Apoptosis Reduction in the Cisplatin-Resistant A431 Cell Line by Bcl-2 and CPP32
  publication-title: Chemotherapy
  doi: 10.1159/000007258
– volume: 97
  year: 2006
  ident: B172
  article-title: Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, Induces Apoptosis Through Activation of Bax in Human Gallbladder Adenocarcinoma Cells
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.20678
– volume: 22
  year: 2004
  ident: B166
  article-title: Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial–INTACT 2
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2004.07.215
– volume: 71
  start-page: 1698S
  year: 2000
  ident: B184
  article-title: Tea Polyphenols: Prevention of Cancer and Optimizing Health
  publication-title: Am J Clin Nutr
  doi: 10.1093/ajcn/71.6.1698S
– volume: 19
  year: 2013
  ident: B122
  article-title: Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-12-1818
– volume: 46
  year: 2006
  ident: B105
  article-title: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT Pathways in Malignant Transformation and Drug Resistance
  publication-title: Adv Enzyme Regul
  doi: 10.1016/j.advenzreg.2006.01.004
– volume: 8
  year: 2003
  ident: B176
  article-title: FDA Drug Approval Summary: Gefitinib (ZD1839)(Iressa®) Tablets
  publication-title: Oncol
  doi: 10.1634/theoncologist.8-4-303
– volume: 19
  start-page: 1
  year: 2019
  ident: B219
  article-title: (–)-Epigallocatechin-3-Gallate Derivatives Combined With Cisplatin Exhibit Synergistic Inhibitory Effects on non-Small-Cell Lung Cancer Cells
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-019-0981-0
– volume: 9
  year: 1989
  ident: B59
  article-title: The Bcl-2 Candidate Proto-Oncogene Product is a 24-Kilodalton Integral-Membrane Protein Highly Expressed in Lymphoid Cell Lines and Lymphomas Carrying the T(14;18) Translocation
  publication-title: Mol Cell Biol
  doi: 10.1128/mcb.9.2.701-710.1989
– volume: 62
  year: 2010
  ident: B247
  article-title: Review on Molecular and Therapeutic Potential of Thymoquinone in Cancer
  publication-title: Nutr Cancer
  doi: 10.1080/01635581.2010.509832
– volume: 43
  year: 2007
  ident: B115
  article-title: High EGFR Expression Predicts Poor Prognosis in Patients With Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: A TMA-Based Immunohistochemical Analysis
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2006.02.009
– volume: 19
  year: 2013
  ident: B329
  article-title: ABT-199, a Potent and Selective BCL-2 Inhibitor, Achieves Antitumor Activity While Sparing Platelets
  publication-title: Nat Med
  doi: 10.1038/nm.3048
– volume: 8
  year: 1993
  ident: B90
  article-title: A Complete Description of the EGF-Receptor Exon Structure: Implication in Oncogenic Activation and Domain Evolution
  publication-title: Oncogene
– volume: 9
  start-page: 174
  year: 2019
  ident: B319
  article-title: Fisetin and Quercetin: Promising Flavonoids With Chemopreventive Potential
  publication-title: Biomolecules
  doi: 10.3390/biom9050174
– volume: 7
  year: 2020
  ident: B15
  article-title: Role of PI3K and EGFR in Oral Cancer Progression and Drug Resistance
  publication-title: Int J Res Appl Sci Biotechnol
  doi: 10.31033/ijrasb.7.6.14
– volume: 7
  start-page: 84594
  year: 2016
  ident: B327
  article-title: Combining a GSI and BCL-2 Inhibitor to Overcome Melanoma's Resistance to Current Treatments
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.13141
– volume: 133
  start-page: 7
  year: 2019
  ident: B332
  article-title: Venetoclax Combined With Decitabine or Azacitidine in Treatment-Naive, Elderly Patients With Acute Myeloid Leukemia
  publication-title: Blood
  doi: 10.1182/blood-2018-08-868752
– volume: 124
  start-page: 3645
  year: 2014
  ident: B337
  article-title: MCL1 Targeting Agent Homoharringtonine Exerts Strong Cytotoxicity Towards Diffuse Large B-Cell Lymphoma (DLBCL) Cells and Synergizes With BCL2 Targeting Agent ABT199 in Eliminating BCL2-Positive DLBCL Cells
  publication-title: Blood
  doi: 10.1182/blood.V124.21.3645.3645
– volume: 82
  year: 2000
  ident: B356
  article-title: Induction of Apoptosis and Activation of the Caspase Cascade by Anti-EGF Receptor Monoclonal Antibodies in DiFi Human Colon Cancer Cells do Not Involve the C-Jun N-Terminal Kinase Activity
  publication-title: Br J Cancer
  doi: 10.1054/bjoc.2000.1201
– volume: 27
  year: 2009
  ident: B123
  article-title: First-Line Gefitinib for Patients With Advanced non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.18.7658
– volume: 11
  year: 2018
  ident: B137
  article-title: Apigenin Inhibits Proliferation of Human Chondrosarcoma Cells via Cell Cycle Arrest and Mitochondrial Apoptosis Induced by ROS Generation-an In Vitro and In Vivo Study
  publication-title: Int J Clin Exp Med
– volume: 117
  year: 2005
  ident: B287
  article-title: Thymoquinone Induces Apoptosis Through Activation of Caspase-8 and Mitochondrial Events in P53-Null Myeloblastic Leukemia HL-60 Cells
  publication-title: Int J Cancer
  doi: 10.1002/ijc.21205
– volume: 37
  start-page: 16
  year: 2001
  ident: B131
  article-title: The EGFR as a Target for Anticancer Therapy—Focus on Cetuximab
  publication-title: Eur J Cancer
  doi: 10.1016/S0959-8049(01)00233-7
– volume: 79
  year: 2016
  ident: B135
  article-title: Natural Products as Sources of New Drugs From 1981 to 2014
  publication-title: J Natural Products
  doi: 10.1021/acs.jnatprod.5b01055
– year: 1991
  ident: B268
  article-title: Inhibitory Effects of Nigella Sativa and Saffron (Crocus Sativus) on Chemical Carcinogenesis in Mice
  doi: 10.1080/01635589109514142
– volume: 26
  start-page: 894
  year: 2015
  ident: B124
  article-title: A Randomized Phase II Study of the MEK1/MEK2 Inhibitor Trametinib (GSK1120212) Compared With Docetaxel in KRAS-Mutant Advanced non-Small-Cell Lung Cancer (NSCLC)
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdv072
– volume: 37
  year: 2016
  ident: B114
  article-title: Reversion-Inducing Cysteine-Rich Protein With Kazal Motifs and its Regulation by Glycogen Synthase Kinase 3 Signaling in Oral Cancer
  publication-title: Tumor Biol
  doi: 10.1007/s13277-016-5362-x
– volume: 10
  start-page: 1
  year: 2020
  ident: B294
  article-title: Quercetin and Cancer: New Insights Into its Therapeutic Effects on Ovarian Cancer Cells
  publication-title: Cell Biosci
  doi: 10.1186/s13578-020-00397-0
– volume: 13
  year: 2006
  ident: B65
  article-title: Proapoptotic Multidomain Bcl-2/Bax-Family Proteins: Mechanisms, Physiological Roles, and Therapeutic Opportunities
  publication-title: Cell Death Differ
  doi: 10.1038/sj.cdd.4401975
– volume: 62
  year: 2013
  ident: B71
  article-title: Bcl-2 and Bcl-xL Suppress Glucose Signaling in Pancreatic β-Cells
  publication-title: Diabetes
  doi: 10.2337/db11-1464
– volume: 12
  start-page: 1
  year: 2019
  ident: B128
  article-title: Emerging Therapies for non-Small Cell Lung Cancer
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-019-0731-8
– volume: 13
  start-page: 93
  year: 2002
  ident: B158
  article-title: Antitumor Activity of Protein Kinase C Inhibitors and Cisplatin in Human Head and Neck Squamous Cell Carcinoma Lines
  publication-title: Anticancer Drugs
  doi: 10.1097/00001813-200201000-00011
– volume: 1
  start-page: 1
  year: 2011
  ident: B250
  article-title: Antidiabetic Properties of a Spice Plant Nigella Sativa
  publication-title: J Endocrinol Metab
  doi: 10.4021/jem12e
– volume: 13
  year: 2008
  ident: B201
  article-title: EGCG Inhibits Growth, Invasion, Angiogenesis and Metastasis of Pancreatic Cancer
  publication-title: Front Biosci
  doi: 10.2741/2691
– volume: 85
  year: 1999
  ident: B83
  article-title: Spontaneous Apoptosis in Laryngeal Squamous Cell Carcinoma is Independent of Bcl-2 and Bax Protein Expression
  publication-title: Cancer
  doi: 10.1002/(SICI)1097-0142(19990201)85:3<591::AID-CNCR9>3.0.CO;2-F
– volume: 68
  year: 2008
  ident: B150
  article-title: ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-5836
– volume: 60
  year: 2012
  ident: B195
  article-title: (–)-Epigallocatechin Gallate Induces Fas/CD95-Mediated Apoptosis Through Inhibiting Constitutive and IL-6-Induced JAK/STAT3 Signaling in Head and Neck Squamous Cell Carcinoma Cells
  publication-title: J Agric Food Chem
  doi: 10.1021/jf204362n
– volume: 29
  start-page: 909
  year: 2011
  ident: B224
  article-title: Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.31.6208
– volume: 92
  year: 2005
  ident: B56
  article-title: Bcl-2 Expression Predicts Radiotherapy Failure in Laryngeal Cancer
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6602647
– volume: 292
  year: 2001
  ident: B41
  article-title: Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death
  publication-title: Science
  doi: 10.1126/science.1059108
– volume: 10
  start-page: 53
  year: 2016
  ident: B110
  article-title: Targeting the KRAS Variant for Treatment of non-Small Cell Lung Cancer: Potential Therapeutic Applications
  publication-title: Expert Rev Respir Med
  doi: 10.1586/17476348.2016.1115349
– volume: 5
  year: 2006
  ident: B118
  article-title: EGFR Targeted Therapy: View From Biological Standpoint
  publication-title: Cell Cycle
  doi: 10.4161/cc.5.18.3277
– volume: 24
  year: 2013
  ident: B151
  article-title: Targeting BCL-2 With the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2013.06.002
– volume: 8
  start-page: 5
  year: 2005
  ident: B221
  article-title: Killing Cancer Cells by Flipping the Bcl-2/Bax Switch
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2005.06.012
– volume: 6
  year: 2000
  ident: B339
  article-title: Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa), an Epidermal Growth Factor Receptor-Selective Tyrosine Kinase Inhibitor
  publication-title: Clin Cancer Res
– volume: 38
  year: 2017
  ident: B293
  article-title: Anticancer and Apoptosis−Inducing Effects of Quercetin In Vitro and In Vivo
  publication-title: Oncol Rep
  doi: 10.3892/or.2017.5766
– volume: 8
  start-page: 108522
  year: 2017
  ident: B232
  article-title: Mimicking the BIM BH3 Domain Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant non-Small Cell Lung Cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.19411
– volume: 102
  start-page: 37
  year: 2004
  ident: B92
  article-title: Signaling Through the Epidermal Growth Factor Receptor During the Development of Malignancy
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2004.01.002
– volume: 29
  start-page: 1
  year: 2010
  ident: B252
  article-title: Thymoquinone and Cisplatin as a Therapeutic Combination in Lung Cancer: In Vitro and In Vivo
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/1756-9966-29-87
– volume: 59
  start-page: 790
  year: 2006
  ident: B72
  article-title: Immunohistochemical Markers of Prognosis in non-Small Cell Lung Cancer: A Review and Proposal for a Multiphase Approach to Marker Evaluation
  publication-title: J Clin Pathol
  doi: 10.1136/jcp.2005.031351
– volume: 55
  year: 1995
  ident: B87
  article-title: Overexpression of Bcl-2 Protects Prostate Cancer Cells From Apoptosis In Vitro and Confers Resistance to Androgen Depletion In Vivo
  publication-title: Cancer Res
– volume: 108
  start-page: 96
  year: 2017
  ident: B106
  article-title: Synergy Between Next Generation EGFR Tyrosine Kinase Inhibitors and miR-34a in the Inhibition of non-Small Cell Lung Cancer
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2017.02.020
– volume: 21
  year: 2008
  ident: B111
  article-title: Lung Adenocarcinoma: Guiding EGFR-Targeted Therapy and Beyond
  publication-title: Modern Pathol
  doi: 10.1038/modpathol.3801018
– volume: 1
  year: 2018
  ident: B138
  article-title: Combination of Baicalein and Docetaxel Additively Inhibits the Growth of non-Small Cell Lung Cancer In Vivo
  publication-title: Tradit Med Modern Med
  doi: 10.1142/S2575900018500131
– volume: 143
  start-page: e1S
  year: 2013
  ident: B2
  article-title: Epidemiology of Lung Cancer: Diagnosis and Management of Lung Cancer: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
  publication-title: Chest
  doi: 10.1378/chest.12-2345
– volume: 26
  year: 2006
  ident: B322
  article-title: The Antiproliferative Effect of Quercetin in Cancer Cells is Mediated via Inhibition of the PI3K-Akt/PKB Pathway
  publication-title: Anticancer Res
– volume: 60
  year: 2012
  ident: B206
  article-title: Epigallocatechin Gallate Induces Fas/CD95-Mediated Apoptosis Through Inhibiting Constitutive and IL-6-Induced JAK/STAT3 Signaling in Head and Neck Squamous Cell Carcinoma Cells
  publication-title: J Agric Food Chem
  doi: 10.1021/jf204362n
– volume: 1
  start-page: 497
  year: 2010
  ident: B6
  article-title: EGFR-Mutated Lung Cancer: A Paradigm of Molecular Oncology
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.186
– volume: 1
  year: 2002
  ident: B155
  article-title: The Apoptotic Effect of HA14-1, a Bcl-2-Interacting Small Molecular Compound, Requires Bax Translocation and is Enhanced by PK11195
  publication-title: Mol Cancer Ther
– volume: 62
  year: 2002
  ident: B175
  article-title: ZD1839 (Iressa): An Orally Active Inhibitor of Epidermal Growth Factor Signaling With Potential for Cancer Therapy
  publication-title: Cancer Res
– volume: 25
  start-page: 3146
  year: 2020
  ident: B211
  article-title: Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and its Role in the Therapy of Various Types of Cancer
  publication-title: Molecules
  doi: 10.3390/molecules25143146
– volume: 6
  year: 2013
  ident: B216
  article-title: Epigallocatechin-3-Gallate Inhibits IGF-I-Stimulated Lung Cancer Angiogenesis Through Downregulation of HIF-1α and VEGF Expression
  publication-title: Lifestyle Genomics
  doi: 10.1159/000354402
– volume: 435
  year: 2005
  ident: B222
  article-title: An Inhibitor of Bcl-2 Family Proteins Induces Regression of Solid Tumours
  publication-title: Nature
  doi: 10.1038/nature03579
– volume: 36
  year: 2013
  ident: B299
  article-title: Quercetin Potentiates Apoptosis by Inhibiting Nuclear factor-kappaB Signaling in H460 Lung Cancer Cells
  publication-title: Biol Pharm Bull
  doi: 10.1248/bpb.b12-01004
– volume: 11
  year: 2008
  ident: B192
  article-title: Regulating the Age-Related Oxidative Damage, Mitochondrial Integrity, and Antioxidative Enzyme Activity in Fischer 344 Rats by Supplementation of the Antioxidant Epigallocatechin-3-Gallate
  publication-title: Rejuvenation Res
  doi: 10.1089/rej.2007.0645
– volume: 2
  year: 2012
  ident: B14
  article-title: Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-12-0103
– volume: 12
  year: 2005
  ident: B168
  article-title: Molecular Aspects of Gefitinib Antiproliferative and Pro-Apoptotic Effects in PTEN-Positive and PTEN-Negative Prostate Cancer Cell Lines
  publication-title: Endoc-Rel Cancer
  doi: 10.1677/erc.1.00986
– volume: 69
  year: 2009
  ident: B255
  article-title: Antitumor Activity of Gemcitabine and Oxaliplatin is Augmented by Thymoquinone in Pancreatic Cancer
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-4235
– volume: 56
  year: 2003
  ident: B43
  article-title: Molecular Detection of the G(-248)A BAX Promoter Nucleotide Change in B Cell Chronic Lymphocytic Leukaemia
  publication-title: Mol Pathol
  doi: 10.1136/mp.56.4.205
– volume: 89
  start-page: 55
  year: 2003
  ident: B75
  article-title: Role of Bcl-2 as a Prognostic Factor for Survival in Lung Cancer: A Systematic Review of the Literature With Meta-Analysis
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6601095
– volume: 6
  start-page: 495
  year: 2008
  ident: B261
  article-title: From Here to Eternity-the Secret of Pharaohs: Therapeutic Potential of Black Cumin Seeds and Beyond
  publication-title: Cancer Ther
– volume: 84
  year: 2003
  ident: B265
  article-title: Gastroprotective Activity of Nigella Sativa Oil and its Constituent, Thymoquinone, Against Gastric Mucosal Injury Induced by Ischaemia/Reperfusion in Rats
  publication-title: J Ethnopharmacol
  doi: 10.1016/S0378-8741(02)00324-0
– volume: 34
  start-page: 3638
  year: 2016
  ident: B126
  article-title: The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced non–Small-Cell Lung Cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2015.66.0084
– volume: 150
  year: 2012
  ident: B7
  article-title: Mapping the Hallmarks of Lung Adenocarcinoma With Massively Parallel Sequencing
  publication-title: Cell
  doi: 10.1016/j.cell.2012.08.029
– year: 2003
  ident: B182
  article-title: Cancer Chemopreventive Activity and Bioavailability of Tea and Tea Polyphenols
  publication-title: Mutat Res
  doi: 10.1016/S0027-5107(02)00336-6
– volume: 9
  year: 2018
  ident: B199
  article-title: Suppressing Glucose Metabolism With Epigallocatechin-3-Gallate (EGCG) Reduces Breast Cancer Cell Growth in Preclinical Models
  publication-title: Food Funct
  doi: 10.1039/C8FO01397G
– volume: 377
  year: 2017
  ident: B103
  article-title: Precision Diagnosis and Treatment for Advanced non–Small-Cell Lung Cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra1703413
– volume: 2012
  start-page: 521215
  year: 2012
  ident: B117
  article-title: Antiepidermal Growth Factor Receptor Therapy in Squamous Cell Carcinoma of the Head and Neck
  publication-title: J Oncol
  doi: 10.1155/2012/521215
– volume: 10
  year: 2004
  ident: B157
  article-title: Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis is Inhibited by Bcl-2 But Restored by the Small Molecule Bcl-2 Inhibitor, HA 14-1, in Human Colon Cancer Cells
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-1289
– volume: 147
  start-page: 112658
  year: 2022
  ident: B282
  article-title: Natural Products can be Used in Therapeutic Management of COVID-19: Probable Mechanistic Insights
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2022.112658
– volume: 5
  start-page: 8528
  year: 2014
  ident: B19
  article-title: Inhibition of Lung Tumor Growth by Targeting EGFR/VEGFR-Akt/NF-κb Pathways With Novel Theanine Derivatives
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.2336
– volume: 86
  year: 2002
  ident: B341
  article-title: ZD1839 (‘Iressa’), a Specific Oral Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, Potentiates Radiotherapy in a Human Colorectal Cancer Xenograft Model
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6600182
– volume: 11
  year: 2016
  ident: B236
  article-title: Enhanced Anticancer Effect of ABT-737 in Combination With Naringenin on Gastric Cancer Cells
  publication-title: Exp Ther Med
  doi: 10.3892/etm.2015.2912
– volume: 19
  year: 2008
  ident: B191
  article-title: The Nitration of Platelet Vasodilator Stimulated Phosphoprotein Following Exposure to Low Concentrations of Hydrogen Peroxide
  publication-title: Platelets
  doi: 10.1080/09537100801915142
– volume: 17
  start-page: 984
  year: 2016
  ident: B350
  article-title: An Open-Label Phase 2 Trial of Dabrafenib Plus Trametinib in Patients With Previously Treated BRAF V600E–mutant Metastatic non-Small Cell Lung Cancer
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(16)30146-2
– volume: 8
  start-page: 71358
  year: 2017
  ident: B21
  article-title: The Resistance Mechanisms and Treatment Strategies for EGFR-Mutant Advanced non-Small-Cell Lung Cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.20311
– volume: 30
  year: 2012
  ident: B149
  article-title: Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.34.7898
– volume: 29
  start-page: CRA7506
  year: 2011
  ident: B10
  article-title: Identification of Driver Mutations in Tumor Specimens From 1,000 Patients With Lung Adenocarcinoma: The Nci’s Lung Cancer Mutation Consortium (LCMC)
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2011.29.15_suppl.cra7506
– volume: 12
  year: 2007
  ident: B24
  article-title: Response to Treatment and Survival of Patients With non-Small Cell Lung Cancer Undergoing Somatic EGFR Mutation Testing
  publication-title: Oncol
  doi: 10.1634/theoncologist.12-1-90
– volume: 65
  start-page: 87
  year: 2015
  ident: B1
  article-title: Global Cancer Statistics 2012
  publication-title: CA: Cancer J Clin
  doi: 10.3322/caac.21262
– volume: 7
  start-page: e52483
  year: 2012
  ident: B241
  article-title: ABT-737 Induces Bim Expression via JNK Signaling Pathway and its Effect on the Radiation Sensitivity of HeLa Cells
  publication-title: PloS One
  doi: 10.1371/journal.pone.0052483
– volume: 42
  year: 2015
  ident: B119
  article-title: Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy
  publication-title: Paper Presented At: Semin Oncol (Elsevier)
  doi: 10.1053/j.seminoncol.2015.05.007
– volume: 9
  start-page: 12261
  year: 2018
  ident: B212
  article-title: EGCG Inhibited Bladder Cancer T24 and 5637 Cell Proliferation and Migration via PI3K/AKT Pathway
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.24301
– year: 2018
  ident: B283
  article-title: Thymoquinone Enhanced the Tumoricidal Activity of NK Cells Against Lung Cancer
  publication-title: (Am Assoc Immnol)
– volume: 97
  year: 2005
  ident: B113
  article-title: Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/dji055
– volume: 287
  year: 2012
  ident: B240
  article-title: Tyrosine-Phosphorylated Caveolin-1 (Tyr-14) Increases Sensitivity to Paclitaxel by Inhibiting BCL2 and BCLxL Proteins via C-Jun N-Terminal Kinase (JNK)
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M111.304022
– volume: 38
  start-page: 638
  year: 2015
  ident: B300
  article-title: Quercetin Enhances Cisplatin Sensitivity of Human Osteosarcoma Cells by Modulating microRNA-217-KRAS Axis
  publication-title: Mol Cells
  doi: 10.14348/molcells.2015.0037
– volume: 348
  year: 1990
  ident: B58
  article-title: Bcl-2 is an Inner Mitochondrial Membrane Protein That Blocks Programmed Cell Death
  publication-title: Nature
  doi: 10.1038/348334a0
– volume: 10
  year: 2006
  ident: B231
  article-title: The BH3 Mimetic ABT-737 Targets Selective Bcl-2 Proteins and Efficiently Induces Apoptosis via Bak/Bax If Mcl-1 is Neutralized
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2006.08.027
– volume: 455
  year: 2008
  ident: B102
  article-title: Somatic Mutations Affect Key Pathways in Lung Adenocarcinoma
  publication-title: Nature
  doi: 10.1038/nature07423
– volume: 101
  year: 2004
  ident: B96
  article-title: EGF Receptor Gene Mutations are Common in Lung Cancers From “Never Smokers” and are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.0405220101
– volume: 17
  year: 2005
  ident: B63
  article-title: Life in the Balance: How BH3-Only Proteins Induce Apoptosis
  publication-title: Curr Opin Cell Biol
  doi: 10.1016/j.ceb.2005.10.001
– volume: 86
  year: 2005
  ident: B256
  article-title: The Biochemical and Morphological Alterations Following Administration of Melatonin, Retinoic Acid and Nigella Sativa in Mammary Carcinoma: An Animal Model
  publication-title: Int J Exp Pathol
  doi: 10.1111/j.0959-9673.2005.00448.x
– volume: 76
  year: 2013
  ident: B9
  article-title: Update of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in non-Small-Cell Lung Cancer
  publication-title: J Chin Med Assoc
  doi: 10.1016/j.jcma.2013.01.010
– volume: 23
  year: 2009
  ident: B274
  article-title: Thymoquinone Supplementation Induces Quinone Reductase and Glutathione Transferase in Mice Liver: Possible Role in Protection Against Chemical Carcinogenesis and Toxicity
  publication-title: Phytother Res
  doi: 10.1002/ptr.2766
– volume: 1864
  year: 2017
  ident: B292
  article-title: Quercetin Suppresses the Metastatic Ability of Lung Cancer Through Inhibiting Snail-Dependent Akt Activation and Snail-Independent ADAM9 Expression Pathways
  publication-title: Biochim Biophys Acta (BBA)-Mol Cell Res
  doi: 10.1016/j.bbamcr.2017.06.017
– volume: 4
  start-page: e294
  year: 2007
  ident: B233
  article-title: Induction of BIM is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
  publication-title: PloS Med
  doi: 10.1371/journal.pmed.0040294
– volume: 64
  year: 2004
  ident: B130
  article-title: BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-04-1443
– volume: 19
  year: 2013
  ident: B348
  article-title: Clinical, Pathologic, and Biologic Features Associated With BRAF Mutations in non–Small Cell Lung Cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-13-0657
– volume: 19
  year: 1999
  ident: B93
  article-title: Novel Roles of Specific Isoforms of Protein Kinase C in Activation of the C-Fos Serum Response Element
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.19.2.1313
– volume: 70
  year: 2010
  ident: B141
  article-title: Blueberry Phytochemicals Inhibit Growth and Metastatic Potential of MDA-MB-231 Breast Cancer Cells Through Modulation of the Phosphatidylinositol 3-Kinase Pathway
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-09-3565
– volume: 41
  year: 2004
  ident: B174
  article-title: Targeting the Epidermal Growth Factor Receptor by Gefitinib for Treatment of Hepatocellular Carcinoma
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2004.08.024
– volume: 45
  start-page: 195
  year: 2003
  ident: B257
  article-title: Chemopreventive Potential of Volatile Oil From Black Cumin (Nigella Sativa L.) Seeds Against Rat Colon Carcinogenesis
  publication-title: Nutr Cancer
  doi: 10.1207/S15327914NC4502_09
– volume: 63
  year: 2003
  ident: B145
  article-title: Cancer Prevention by Tea Polyphenols is Linked to Their Direct Inhibition of Antiapoptotic Bcl-2-Family Proteins
  publication-title: Cancer Res
– volume: 226
  year: 1984
  ident: B57
  article-title: Cloning of the Chromosome Breakpoint of Neoplastic B Cells With the T(14;18) Chromosome Translocation
  publication-title: Science
  doi: 10.1126/science.6093263
– volume: 8
  start-page: 129
  year: 2015
  ident: B328
  article-title: ABT-199 (Venetoclax) and BCL-2 Inhibitors in Clinical Development
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-015-0224-3
– volume: 124
  start-page: 53
  year: 2018
  ident: B125
  article-title: KRAS-Mutant non-Small Cell Lung Cancer: From Biology to Therapy
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2018.07.013
– volume: 501
  start-page: 65
  year: 2010
  ident: B193
  article-title: The Antioxidant and Pro-Oxidant Activities of Green Tea Polyphenols: A Role in Cancer Prevention
  publication-title: Arch Biochem Biophys
  doi: 10.1016/j.abb.2010.06.013
– volume: 17
  start-page: 27
  year: 2016
  ident: B18
  article-title: Combination With Vorinostat Overcomes ABT-263 (Navitoclax) Resistance of Small Cell Lung Cancer
  publication-title: Cancer Biol Ther
  doi: 10.1080/15384047.2015.1108485
– volume: 6
  start-page: 239
  year: 2013
  ident: B266
  article-title: The Effect of Vascular Endothelial Growth Factor in the Progression of Bladder Cancer and Diabetic Retinopathy
  publication-title: Int J Clin Exp Med
– volume: 15
  year: 2018
  ident: B77
  article-title: Expression of Bcl-2 is a Favorable Prognostic Biomarker in Lung Squamous Cell Carcinoma
  publication-title: Oncol Lett
  doi: 10.3892/ol.2018.8198
– volume: 63
  start-page: 16
  year: 2022
  ident: B223
  article-title: ABT-737, a BH3 Mimetic, Enhances the Therapeutic Effects of Ionizing Radiation in K-Ras Mutant Non-Small Cell Lung Cancer Preclinical Model
  publication-title: Yonsei Med J
  doi: 10.3349/ymj.2022.63.1.16
– volume: 139
  year: 2009
  ident: B304
  article-title: Quercetin may Suppress Rat Aberrant Crypt Foci Formation by Suppressing Inflammatory Mediators That Influence Proliferation and Apoptosis
  publication-title: J Nutr
  doi: 10.3945/jn.108.096271
– volume: 19
  year: 2014
  ident: B358
  article-title: Inhibition of the JAK/STAT Pathway With Ruxolitinib Overcomes Cisplatin Resistance in non-Small-Cell Lung Cancer NSCLC
  publication-title: Apoptosis
  doi: 10.1007/s10495-014-1030-z
– volume: 74
  year: 1993
  ident: B39
  article-title: Bcl-2 Heterodimerizes In Vivo With a Conserved Homolog, Bax, That Accelerates Programmed Cell Death
  publication-title: Cell
  doi: 10.1016/0092-8674(93)90509-O
– volume: 369
  year: 1994
  ident: B69
  article-title: BH1 and BH2 Domains of Bcl-2 are Required for Inhibition of Apoptosis and Heterodimerization With Bax
  publication-title: Nature
  doi: 10.1038/369321a0
– volume: 10
  year: 2010
  ident: B23
  article-title: Rational, Biologically Based Treatment of EGFR-Mutant non-Small-Cell Lung Cancer
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2947
– volume: 12
  year: 2011
  ident: B342
  article-title: Erlotinib Versus Chemotherapy as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive non-Small-Cell Lung Cancer (OPTIMAL, CTONG-0802): A Multicentre, Open-Label, Randomised, Phase 3 Study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(11)70184-X
– volume: 23
  year: 2019
  ident: B27
  article-title: Trans-3, 5, 4´-Trimethoxystilbene Reduced Gefitinib Resistance in NSCLC s via Suppressing MAPK/Akt/Bcl-2 Pathway by Upregulation of miR-345 and miR-498
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.14086
– volume: 2
  year: 2001
  ident: B91
  article-title: Untangling the ErbB Signalling Network
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/35052073
– volume: 12
  start-page: 761
  year: 2020
  ident: B280
  article-title: Thymoquinone-Loaded Soy-Phospholipid-Based Phytosomes Exhibit Anticancer Potential Against Human Lung Cancer Cells
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics12080761
– volume: 147
  start-page: 1
  year: 2021
  ident: B335
  article-title: Combining Radiation to EGFR and Bcl-2 Blockade: A New Approach to Target Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-021-03593-8
– volume: 350
  year: 2004
  ident: B95
  article-title: Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of non–Small-Cell Lung Cancer to Gefitinib
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa040938
– volume: 38
  year: 2019
  ident: B22
  article-title: Targeting FGFR Overcomes EMT-Mediated Resistance in EGFR Mutant non-Small Cell Lung Cancer
  publication-title: Oncogene
  doi: 10.1038/s41388-019-0887-2
– volume: 10
  start-page: 84
  year: 2016
  ident: B297
  article-title: Overviews of Biological Importance of Quercetin: A Bioactive Flavonoid
  publication-title: Pharmacognosy Rev
  doi: 10.4103/0973-7847.194044
– volume: 15
  year: 2009
  ident: B181
  article-title: Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-08-1757
– volume: 23
  year: 2019
  ident: B318
  article-title: Anti-Angiogenic Effect of Quercetin and its 8-Methyl Pentamethyl Ether Derivative in Human Microvascular Endothelial Cells
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.14455
– volume: 5
  year: 2015
  ident: B354
  article-title: Response to MET Inhibitors in Patients With Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
  publication-title: Cancer Discovery
  doi: 10.1158/2159-8290.CD-14-1467
– volume: 19
  year: 2008
  ident: B249
  article-title: The Role of Herbs and Spices in Cancer Prevention
  publication-title: J Nutr Biochem
  doi: 10.1016/j.jnutbio.2007.11.003
– volume: 43
  start-page: 194
  year: 2013
  ident: B196
  article-title: Epigallocatechin-3-Gallate Promotes Apoptosis and Expression of the Caspase 9a Splice Variant in PC3 Prostate Cancer Cells
  publication-title: Int J Oncol
  doi: 10.3892/ijo.2013.1920
– volume: 132135
  year: 2022
  ident: B97
  article-title: Epigallocatechin 3-Gallate: From Green Tea to Cancer Therapeutics
  publication-title: Food Chem
  doi: 10.1016/j.foodchem.2022.132135
– volume: 12
  start-page: 986
  year: 2021
  ident: B203
  article-title: EGCG Binds Intrinsically Disordered N-Terminal Domain of P53 and Disrupts P53-MDM2 Interaction
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-21258-5
– volume: 74
  start-page: 593
  year: 2014
  ident: B226
  article-title: Mechanism-Based Pharmacokinetic/Pharmacodynamic Meta-Analysis of Navitoclax (ABT-263) Induced Thrombocytopenia
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-014-2530-9
– volume: 331
  start-page: 48
  year: 2008
  ident: B258
  article-title: Phenolic Composition and Biological Activities of Tunisian Nigella Sativa L. Shoots and Roots
  publication-title: Comptes Rendus Biol
  doi: 10.1016/j.crvi.2007.11.001
– volume: 21
  year: 2016
  ident: B64
  article-title: BH4 Domain of Bcl-2 as a Novel Target for Cancer Therapy
  publication-title: Drug Discov Today
  doi: 10.1016/j.drudis.2015.11.008
– volume: 2021
  start-page: 6612365
  year: 2021
  ident: B143
  article-title: Combined Treatment of Cinobufotalin and Gefitinib Exhibits Potent Efficacy Against Lung Cancer
  publication-title: Evid-Based Complement Altern Med
  doi: 10.1155/2021/6612365
– volume: 13
  year: 2002
  ident: B296
  article-title: Protective Effect of Quercetin Against Cigarette Tar Extract-Induced Impairment of Erythrocyte Deformability
  publication-title: J Nutr Biochem
  doi: 10.1016/S0955-2863(01)00219-4
– volume: 5
  year: 2012
  ident: B311
  article-title: Quercetin Inhibits Human Breast Cancer Cell Proliferation and Induces Apoptosis via Bcl-2 and Bax Regulation
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2012.845
– volume: 3
  year: 2004
  ident: B170
  article-title: Sensitivity to Gefitinib (Iressa, ZD1839) in non-Small Cell Lung Cancer Cell Lines Correlates With Dependence on the Epidermal Growth Factor (EGF) Receptor/Extracellular Signal-Regulated Kinase 1/2 and EGF Receptor/Akt Pathway for Proliferation
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.465.3.4
– volume: 13
  year: 2007
  ident: B129
  article-title: KRAS Mutation is an Important Predictor of Resistance to Therapy With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in non–Small-Cell Lung Cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-3043
– volume: 4
  start-page: e315
  year: 2007
  ident: B25
  article-title: BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers With Oncogenic EGFR Mutations
  publication-title: PloS Med
  doi: 10.1371/journal.pmed.0040315
– volume: 26
  start-page: 6677
  year: 2021
  ident: B98
  article-title: Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
  publication-title: Molecules
  doi: 10.3390/molecules26216677
– volume: 184
  year: 2010
  ident: B107
  article-title: MicroRNAs Reduce Tumor Growth and Contribute to Enhance Cytotoxicity Induced by Gefitinib in non-Small Cell Lung Cancer
  publication-title: Chemico-biol Interact
  doi: 10.1016/j.cbi.2010.01.025
– volume: 41
  start-page: 47
  year: 2018
  ident: B134
  article-title: Glycogen Synthase Kinase-3β Mediated Regulation of Matrix Metalloproteinase-9 and its Involvement in Oral Squamous Cell Carcinoma Progression and Invasion
  publication-title: Cell Oncol
  doi: 10.1007/s13402-017-0358-0
– volume: 6
  start-page: a020768
  year: 2014
  ident: B338
  article-title: The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases
  publication-title: Cold Spring Harbor Perspect Biol
  doi: 10.1101/cshperspect.a020768
– volume: 26
  year: 2006
  ident: B315
  article-title: > Role of Mitochondria in Quercetin-Enhanced Chemotherapeutic Response in Human Non-Small Cell Lung Carcinoma H-520 Cells
  publication-title: Anticancer Res
– volume: 1
  year: 2010
  ident: B324
  article-title: Quercetin and Sulforaphane in Combination Suppress the Progression of Melanoma Through the Down−Regulation of Matrix Metalloproteinase-9
  publication-title: Exp Ther Med
  doi: 10.3892/etm.2010.144
– volume: 8
  year: 2002
  ident: B44
  article-title: Tumor-Cell Resistance to Death Receptor–Induced Apoptosis Through Mutational Inactivation of the Proapoptotic Bcl-2 Homolog Bax
  publication-title: Nat Med
  doi: 10.1038/nm0302-274
– volume: 6
  start-page: 224
  year: 2006
  ident: B84
  article-title: Identification of Genes Associated With Cisplatin Resistance in Human Oral Squamous Cell Carcinoma Cell Line
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-6-224
– volume: 24
  year: 2018
  ident: B330
  article-title: Venetoclax is Effective in Small-Cell Lung Cancers With High BCL-2 Expression
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-17-1606
– volume: 12
  start-page: S237
  year: 2016
  ident: B307
  article-title: Quercetin Suppresses the Migration and Invasion in Human Colon Cancer Caco-2 Cells Through Regulating Toll-Like Receptor 4/Nuclear Factor-Kappa B Pathway
  publication-title: Pharmacognosy Magazine
  doi: 10.4103/0973-1296.182154
– volume: 131
  year: 2005
  ident: B310
  article-title: Quercetin-Induced Growth Inhibition and Cell Death in Prostatic Carcinoma Cells (PC-3) are Associated With Increase in P21 and Hypophosphorylated Retinoblastoma Proteins Expression
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-005-0005-4
– volume: 89
  year: 2015
  ident: B298
  article-title: Quercetin Induces Mitochondrial-Derived Apoptosis via Reactive Oxygen Species-Mediated ERK Activation in HL-60 Leukemia Cells and Xenograft
  publication-title: Arch Toxicol
  doi: 10.1007/s00204-014-1300-0
– volume: 127
  year: 2010
  ident: B259
  article-title: Antimutagenic Effects of Ethanolic Extracts From Selected Palestinian Medicinal Plants
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2009.11.001
– volume: 123
  year: 2008
  ident: B153
  article-title: TW-37, a Small-Molecule Inhibitor of Bcl-2, Inhibits Cell Growth and Invasion in Pancreatic Cancer
  publication-title: Int J Cancer
  doi: 10.1002/ijc.23610
– volume: 8
  year: 1999
  ident: B264
  article-title: Inhibition of Benzo (a) Pyrene-Induced Forestomach Carcinogenesis in Mice by Thymoquinone
  publication-title: Eur J Cancer Prevent: Off J Eur Cancer Prev Organisation (ECP)
  doi: 10.1097/00008469-199910000-00009
– volume: 10
  start-page: 320
  year: 2013
  ident: B347
  article-title: EGFR-Targeted Therapy for non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
  publication-title: Int J Med Sci
  doi: 10.7150/ijms.4609
– volume: 9
  start-page: 47
  year: 2008
  ident: B35
  article-title: The BCL-2 Protein Family: Opposing Activities That Mediate Cell Death
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm2308
– volume: 116
  year: 2004
  ident: B62
  article-title: Cell Death: Critical Control Points
  publication-title: Cell
  doi: 10.1016/S0092-8674(04)00046-7
– volume: 6
  year: 2000
  ident: B340
  article-title: Efficacy of Cytotoxic Agents Against Human Tumor Xenografts is Markedly Enhanced by Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase
  publication-title: Clin Cancer Res
– volume: 4
  year: 2013
  ident: B243
  article-title: Immunomodulatory Effect of Nigella Sativa Oil in the Disease Process of Type 1 Diabetic Rats
  publication-title: Res J Pharmaceut Biol Chem Sci
– volume: 19
  year: 2000
  ident: B228
  article-title: Bcl-2 Family Proteins as Targets for Anticancer Drug Design
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1204087
– volume: 4
  year: 2006
  ident: B306
  article-title: Combination Treatment With Curcumin and Quercetin of Adenomas in Familial Adenomatous Polyposis
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2006.03.020
– volume: 360
  year: 2007
  ident: B187
  article-title: The Green Tea Polyphenol, Epigallocatechin-3-Gallate Inhibits Telomerase and Induces Apoptosis in Drug-Resistant Lung Cancer Cells
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2007.06.030
– volume: 119
  start-page: 33
  year: 2006
  ident: B188
  article-title: Green Tea Polyphenol Stimulates Cancer Preventive Effects of Celecoxib in Human Lung Cancer Cells by Upregulation of GADD153 Gene
  publication-title: Int J Cancer
  doi: 10.1002/ijc.21809
– volume: 63
  year: 1992
  ident: B269
  article-title: Antitumour Principles From Nigella Sativa Seeds
  publication-title: Cancer Lett
  doi: 10.1016/0304-3835(92)90087-C
– volume: 183
  year: 2021
  ident: B94
  article-title: A Review on the Role of TANK-Binding Kinase 1 Signaling in Cancer
  publication-title: Int J Biol Macromol
  doi: 10.1016/j.ijbiomac.2021.06.022
– volume: 45
  year: 1992
  ident: B244
  article-title: Chemical Composition and Microflora of Black Cumin (Nigella Sativa L.) Seeds Growing in Saudi Arabia
  publication-title: Food Chem
  doi: 10.1016/0308-8146(92)90153-S
– volume: 11
  start-page: 1271
  year: 2021
  ident: B316
  article-title: Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin
  publication-title: Biomolecules
  doi: 10.3390/biom11091271
– volume: 17
  year: 2006
  ident: B164
  article-title: Phase II, Open-Label, Randomized Study (SIGN) of Single-Agent Gefitinib (IRESSA) or Docetaxel as Second-Line Therapy in Patients With Advanced (Stage IIIb or IV) non-Small-Cell Lung Cancer
  publication-title: Anti-cancer Drugs
  doi: 10.1097/01.cad.0000203381.99490.ab
– volume: 75
  year: 2009
  ident: B147
  article-title: ABT-737 Synergizes With Chemotherapy to Kill Head and Neck Squamous Cell Carcinoma Cells via a Noxa-Mediated Pathway
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.108.052969
– volume: 68
  year: 2001
  ident: B209
  article-title: Induction of Apoptosis by Green Tea Catechins in Human Prostate Cancer DU145 Cells
  publication-title: Life Sci
  doi: 10.1016/S0024-3205(00)01020-1
– volume: 15
  year: 2020
  ident: B29
  article-title: The Inhibition of Cell Growth Through the EGFR/ERK/MMP-2 Pathway Induced by Ampelopsin in the Human Malignant Melanoma A375 Cell Line
  publication-title: Natural Product Commun
  doi: 10.1177/1934578X20912864
– volume: 383
  year: 2013
  ident: B278
  article-title: Pronounced Transcriptional Regulation of Apoptotic and TNF–NF-Kappa-B Signaling Genes During the Course of Thymoquinone Mediated Apoptosis in HeLa Cells
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-013-1772-x
– volume: 7
  year: 2007
  ident: B26
  article-title: Epidermal Growth Factor Receptor Mutations in Lung Cancer
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2088
– volume: 4
  year: 1989
  ident: B61
  article-title: Stress-Resistance Conferred by High Level of Bcl-2 Alpha Protein in Human B Lymphoblastoid Cell
  publication-title: Oncogene
– volume: 5
  start-page: a008722
  year: 2013
  ident: B70
  article-title: Multiple Functions of BCL-2 Family Proteins
  publication-title: Cold Spring Harbor Perspect Biol
  doi: 10.1101/cshperspect.a008722
– volume: 17
  year: 2016
  ident: B351
  article-title: Dabrafenib in Patients With BRAFV600E-Positive Advanced Non-Small-Cell Lung Cancer: A Single-Arm, Multicentre, Open-Label, Phase 2 Trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(16)00077-2
– volume: 23
  year: 2002
  ident: B200
  article-title: Inhibition of 7,12-Dimethylbenz[a]Anthracene (DMBA)-Induced Oral Carcinogenesis in Hamsters by Tea and Curcumin
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/23.8.1307
– volume: 706
  start-page: 28
  year: 2011
  ident: B267
  article-title: Thymoquinone Up-Regulates PTEN Expression and Induces Apoptosis in Doxorubicin-Resistant Human Breast Cancer Cells
  publication-title: Mutat Research/Fundamental Mol Mech Mutagene
  doi: 10.1016/j.mrfmmm.2010.10.007
– volume: 18
  year: 2013
  ident: B180
  article-title: Activity-Based Kinase Profiling of Approved Tyrosine Kinase Inhibitors
  publication-title: Genes Cells
  doi: 10.1111/gtc.12022
– volume: 5
  start-page: 196
  year: 2000
  ident: B290
  article-title: Antioxidants and Cancer, Part 3: Quercetin
  publication-title: Altern Med Rev: J Clin Ther
– volume: 62
  year: 2002
  ident: B178
  article-title: ZD1839 (Iressa) Induces Antiangiogenic Effects Through Inhibition of Epidermal Growth Factor Receptor Tyrosine Kinase
  publication-title: Cancer Res
– volume: 36
  year: 2016
  ident: B313
  article-title: Effect of Quercetin on the Expression of Bcl-2/Bax Apoptotic Proteins in Endometrial Cells of Lipopolysaccharide-Induced-Abortion
  publication-title: J Tradit Chin Med Chung i Tsa Chih Ying Wen Pan
  doi: 10.1016/s0254-6272(17)30008-0
– volume: 65
  year: 2005
  ident: B179
  article-title: Cellular Targets of Gefitinib
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.379.65.2
– volume: 32
  year: 2018
  ident: B317
  article-title: Interactions of Quercetin With Receptor Tyrosine Kinases Associated With Human Lung Carcinoma
  publication-title: Natural Product Res
  doi: 10.1080/14786419.2017.1385015
– volume: 36
  year: 2015
  ident: B254
  article-title: Thymoquinone Inhibits Proliferation and Invasion of Human Nonsmall-Cell Lung Cancer Cells via ERK Pathway
  publication-title: Tumor Biol
  doi: 10.1007/s13277-014-2628-z
– volume: 278
  year: 2003
  ident: B323
  article-title: Modulation of Pro-Survival Akt/protein Kinase B and ERK1/2 Signaling Cascades by Quercetin and its In Vivo Metabolites Underlie Their Action on Neuronal Viability
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M305063200
– volume: 39
  year: 2003
  ident: B260
  article-title: Effect of Nigella Sativa (N. Sativa L.) and Oxidative Stress on the Survival Pattern of MCF-7 Breast Cancer Cells
  publication-title: Biomed Sci Instrumentation
– volume: 48
  year: 2010
  ident: B271
  article-title: Thymoquinone Supplementation Reverses Acetaminophen-Induced Oxidative Stress, Nitric Oxide Production and Energy Decline in Mice Liver
  publication-title: Food Chem Toxicol
  doi: 10.1016/j.fct.2010.05.072
– volume: 6
  year: 2011
  ident: B305
  article-title: Quercetin Suppresses Cyclooxygenase-2 Expression and Angiogenesis Through Inactivation of P300 Signaling
  publication-title: PloS One
  doi: 10.1371/journal.pone.0022934
– volume: 35
  year: 2016
  ident: B194
  article-title: EGCG Induces Lung Cancer A549 Cell Apoptosis by Regulating Ku70 Acetylation
  publication-title: Oncol Rep
  doi: 10.3892/or.2016.4587
– volume: 69
  year: 2005
  ident: B309
  article-title: Dietary Flavonoids as Proteasome Inhibitors and Apoptosis Inducers in Human Leukemia Cells
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2005.02.022
– volume: 20
  year: 2014
  ident: B55
  article-title: Down-Regulation of BAX Gene During Carcinogenesis and Acquisition of Resistance to 5-FU in Colorectal Cancer
  publication-title: Pathol Oncol Res
  doi: 10.1007/s12253-013-9695-0
– volume: 42
  start-page: 25
  year: 2002
  ident: B186
  article-title: Inhibition of Carcinogenesis by Tea
  publication-title: Annu Rev Pharmacol Toxicol
  doi: 10.1146/annurev.pharmtox.42.082101.154309
– volume: 8
  start-page: 52118
  year: 2017
  ident: B308
  article-title: Quercetin Inhibits Cr (VI)-Induced Malignant Cell Transformation by Targeting miR-21-PDCD4 Signaling Pathway
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.10130
– volume: 15
  start-page: 31
  year: 1996
  ident: B79
  article-title: Expression of Bcl-2—Protein in Small Cell Lung Cancer
  publication-title: Lung Cancer
  doi: 10.1016/0169-5002(96)00568-5
– volume: 15
  year: 2009
  ident: B205
  article-title: The Green Tea Polyphenol EGCG Potentiates the Antiproliferative Activity of C-Met and Epidermal Growth Factor Receptor Inhibitors in non–Small Cell Lung Cancer Cells
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-09-0109
– volume: 12
  year: 2007
  ident: B202
  article-title: Green Tea Polyphenols: Biology and Therapeutic Implications in Cancer
  publication-title: Front Biosci
  doi: 10.2741/2435
– volume: 14
  start-page: 42
  year: 1999
  ident: B51
  article-title: The Relationship Between Cisplatin-Induced Apoptosis and P53, Bcl-2 and Bax Expression in Human Lung Cancer Cells
  publication-title: Korean J Intern Med
  doi: 10.3904/kjim.1999.14.1.42
– volume: 56
  year: 2001
  ident: B303
  article-title: Anti-Inflammatory Properties of Plant Flavonoids. Effects of Rutin, Quercetin and Hesperidin on Adjuvant Arthritis in Rat
  publication-title: Il Farmaco
  doi: 10.1016/S0014-827X(01)01111-9
– volume: 26
  year: 2020
  ident: B320
  article-title: Quercetin Inhibits the Proliferation and Metastasis of Human non-Small Cell Lung Cancer Cell Line: The Key Role of Src-Mediated Fibroblast Growth Factor-Inducible 14 (Fn14)/nuclear Factor Kappa B (NF-κb) Pathway
  publication-title: Med Sci Monit
  doi: 10.12659/MSM.920537
– volume: 24
  year: 2005
  ident: B46
  article-title: G125A Single-Nucleotide Polymorphism in the Human BAX Promoter Affects Gene Expression
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1208377
– volume: 5
  year: 2015
  ident: B352
  article-title: Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
  publication-title: Cancer Discovery
  doi: 10.1158/2159-8290.CD-15-0285
– volume: 16
  year: 2021
  ident: B127
  article-title: Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors for Advanced EGFR+ NSCLC
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2020.11.028
– volume: 7
  start-page: 82013
  year: 2016
  ident: B336
  article-title: Transcriptomic-Metabolomic Reprogramming in EGFR-Mutant NSCLC Early Adaptive Drug Escape Linking Tgfβ2-Bioenergetics-Mitochondrial Priming
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.13307
– volume: 96
  year: 1996
  ident: B251
  article-title: Vegetables, Fruit, and Cancer Prevention: A Review
  publication-title: J Am Dietetic Assoc
  doi: 10.1016/S0002-8223(96)00273-8
– volume: 7
  year: 1988
  ident: B60
  article-title: Alternative Promoters and Exons, Somatic Mutation and Deregulation of the Bcl-2-Ig Fusion Gene in Lymphoma
  publication-title: EMBO J
  doi: 10.1002/j.1460-2075.1988.tb02791.x
– volume: 41
  year: 2019
  ident: B48
  article-title: Role and Regulation of Proapoptotic Bax in Oral Squamous Cell Carcinoma and Drug Resistance
  publication-title: Head Neck
  doi: 10.1002/hed.25471
– volume: 98
  year: 2001
  ident: B66
  article-title: Solution Structure of the Antiapoptotic Protein Bcl-2
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.041619798
– year: 2021
  ident: B100
  article-title: Potential Therapeutic Targets of Klebsiella Pneumoniae: A Multi-Omics Review Perspective
  publication-title: Briefings Funct Genomics
  doi: 10.1093/bfgp/elab038
– volume: 2014
  start-page: 943648
  year: 2014
  ident: B148
  article-title: Targeting BCL2-Proteins for the Treatment of Solid Tumours
  publication-title: Adv Med
  doi: 10.1155/2014/943648
– volume: 20
  start-page: 1
  year: 2008
  ident: B262
  article-title: Black Seed, Nigella Sativa, Deserves More Attention
  publication-title: J Ayub Med Coll Abbottabad
– volume: 10
  year: 2004
  ident: B154
  article-title: In Vitro Effects of the BH3 Mimetic, (-)-Gossypol, on Head and Neck Squamous Cell Carcinoma Cells
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-0551
– volume: 7
  start-page: 493
  year: 2010
  ident: B346
  article-title: Understanding Resistance to EGFR Inhibitors—Impact on Future Treatment Strategies
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2010.97
– volume: 25
  year: 2011
  ident: B189
  article-title: Evaluation of Renal Protective Effects of the Green-Tea (EGCG) and Red Grape Resveratrol: Role of Oxidative Stress and Inflammatory Cytokines
  publication-title: Natural Product Res
  doi: 10.1080/14786419.2010.533669
– volume: 71
  year: 2013
  ident: B215
  article-title: (–)-Epigallocatechin-3-Gallate Inhibits Human Papillomavirus (HPV)-16 Oncoprotein-Induced Angiogenesis in non-Small Cell Lung Cancer Cells by Targeting HIF-1α
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-012-2063-z
– volume: 14
  year: 2007
  ident: B333
  article-title: Bcl-2 Family Proteins are Essential for Platelet Survival
  publication-title: Cell Death Differ
  doi: 10.1038/sj.cdd.4402081
– volume: 40
  start-page: 93
  year: 2014
  ident: B20
  article-title: Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR-Mutant non-Small Cell Lung Cancer: A New Era Begins
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2013.06.002
– volume: 2
  start-page: e17
  year: 2005
  ident: B101
  article-title: KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
  publication-title: PloS Med
  doi: 10.1371/journal.pmed.0020017
– volume: 385
  year: 1997
  ident: B68
  article-title: Bcl-X(L) Forms an Ion Channel in Synthetic Lipid Membranes
  publication-title: Nature
  doi: 10.1038/385353a0
– volume: 22
  year: 2001
  ident: B190
  article-title: Green Tea Polyphenol (–)-Epigallocatechin-3-Gallate Treatment of Human Skin Inhibits Ultraviolet Radiation-Induced Oxidative Stress
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/22.2.287
– volume: 24
  year: 2004
  ident: B76
  article-title: Bcl-2 Protein Expression Correlates With Better Prognosis in Patients With Advanced non-Small Cell Lung Cancer
  publication-title: Anticancer Res
– volume: 27
  start-page: 195
  year: 2009
  ident: B5
  article-title: Optimal Management of Malignant Epidural Spinal Cord Compression
  publication-title: Emergency Med Clinics North Am
  doi: 10.1016/j.emc.2009.02.001
– volume: 25
  year: 2020
  ident: B288
  article-title: Targeting Kinases With Thymoquinone: A Molecular Approach to Cancer Therapeutics
  publication-title: Drug Discov Today
  doi: 10.1016/j.drudis.2020.07.019
– volume: 374
  year: 2016
  ident: B326
  article-title: Targeting BCL2 With Venetoclax in Relapsed Chronic Lymphocytic Leukemia
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1513257
– volume: 21
  year: 2017
  ident: B53
  article-title: The Elevated Activation of NFkappaB and AP-1 is Correlated With Differential Regulation of Bcl-2 and Associated With Oral Squamous Cell Carcinoma Progression and Resistance
  publication-title: Clin Oral Investig
  doi: 10.1007/s00784-017-2074-6
– volume: 10
  start-page: 1
  year: 2020
  ident: B220
  article-title: Anticancer Effects of Epigallocatechin-3-Gallate Nanoemulsion on Lung Cancer Cells Through the Activation of AMP-Activated Protein Kinase Signaling Pathway
  publication-title: Sci Rep
  doi: 10.1038/s41598-020-62136-2
– volume: 8
  year: 2009
  ident: B225
  article-title: Alterations in the Noxa/Mcl-1 Axis Determine Sensitivity of Small Cell Lung Cancer to the BH3 Mimetic ABT-737
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-08-1118
– volume: 103
  year: 2008
  ident: B277
  article-title: Thymoquinone Ameliorates Renal Oxidative Damage and Proliferative Response Induced by Mercuric Chloride in Rats
  publication-title: Basic Clin Pharmacol Toxicol
  doi: 10.1111/j.1742-7843.2008.00260.x
– volume: 10
  year: 2004
  ident: B74
  article-title: Antitumor Efficacy of Oblimersen Bcl-2 Antisense Oligonucleotide Alone and in Combination With Vinorelbine in Xenograft Models of Human Non–Small Cell Lung Cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-1036
– volume: 12
  year: 2022
  ident: B133
  article-title: Therapeutic Implications of Caffeic Acid in Cancer and Neurological Diseases
  publication-title: Front Oncol
  doi: 10.3389/fonc.2022.860508
– volume: 123
  year: 2005
  ident: B45
  article-title: Role of Bax Mutations in Apoptosis in Colorectal Cancers With Microsatellite Instability
  publication-title: Am J Clin Pathol
  doi: 10.1309/JQ2X3RV3L8F9TGYW
– volume: 10
  year: 2001
  ident: B37
  article-title: Bcl2-L-10, a Novel Anti-Apoptotic Member of the Bcl-2 Family, Blocks Apoptosis in the Mitochondria Death Pathway But Not in the Death Receptor Pathway
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/10.21.2329
– volume: 19
  year: 1999
  ident: B245
  article-title: High Performance Liquid Chromatographic Analysis of the Pharmacologically Active Quinones and Related Compounds in the Oil of the Black Seed (Nigella Sativa L.)
  publication-title: J Pharm Biomed Anal
  doi: 10.1016/S0731-7085(98)00300-8
– volume: 27
  year: 2008
  ident: B230
  article-title: Apoptosis-Based Treatment of Glioblastomas With ABT-737, a Novel Small Molecule Inhibitor of Bcl-2 Family Proteins
  publication-title: Oncogene
  doi: 10.1038/onc.2008.259
– volume: 38
  year: 2008
  ident: B50
  article-title: Low Expression of Bax Predicts Poor Prognosis in Resected non-Small Cell Lung Cancer Patients With non-Squamous Histology
  publication-title: Jpn J Clin Oncol
  doi: 10.1093/jjco/hyn089
– volume: 13
  year: 2022
  ident: B99
  article-title: Potential Therapeutic Implications of Caffeic Acid in Cancer Signaling: Past, Present, and Future
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2022.845871
– volume: 316
  year: 2007
  ident: B359
  article-title: MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
  publication-title: Science
  doi: 10.1126/science.1141478
– volume: 31
  year: 2014
  ident: B213
  article-title: Epigallocatechin Gallate Inhibits the Growth of Human Lung Cancer by Directly Targeting the EGFR Signaling Pathway
  publication-title: Oncol Rep
  doi: 10.3892/or.2013.2933
– volume: 6
  year: 2015
  ident: B239
  article-title: Targeting ERK1/2-Bim Signaling Cascades by BH3-Mimetic ABT-737 as an Alternative Therapeutic Strategy for Oral Cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.5523
– volume: 25
  year: 2007
  ident: B112
  article-title: Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.07.3585
– volume: 31
  year: 2007
  ident: B197
  article-title: Epigallocatechin-3 Gallate Induces Growth Inhibition and Apoptosis in Human Breast Cancer Cells Through Survivin Suppression
  publication-title: Int J Oncol
  doi: 10.3892/ijo.31.4.705
– volume: 9
  year: 2009
  ident: B289
  article-title: Quercetin and its Derivatives: Synthesis, Pharmacological Uses With Special Emphasis on Anti-Tumor Properties and Prodrug With Enhanced Bio-Availability
  publication-title: Anti-Cancer Agents Med Chem (Formerly Curr Med Chemistry-Anti-Cancer Agents)
  doi: 10.2174/187152009787313855
– volume: 45
  year: 2009
  ident: B54
  article-title: Expression of Bcl-2 Family Proteins and Associated Clinicopathologic Factors Predict Survival Outcome in Patients With Oral Squamous Cell Carcinoma
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2008.05.021
– volume: 18
  year: 2013
  ident: B276
  article-title: In Vivo Modulation of iNOS Pathway in Hepatocellular Carcinoma by Nigella Sativa
  publication-title: Environ Health Prev Med
  doi: 10.1007/s12199-013-0336-8
– volume: 290
  year: 2003
  ident: B162
  article-title: Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With non–Small Cell Lung Cancer: A Randomized Trial
  publication-title: Jama
  doi: 10.1001/jama.290.16.2149
– volume: 20
  year: 2009
  ident: B116
  article-title: Epidermal Growth Factor Receptor Inhibitors in Cancer Treatment: Advances, Challenges and Opportunities
  publication-title: Anticancer Drugs
  doi: 10.1097/CAD.0b013e3283330590
– volume: 2013
  year: 2013
  ident: B136
  article-title: Phytoagents for Cancer Management: Regulation of Nucleic Acid Oxidation, ROS, and Related Mechanisms
  publication-title: Oxid Med Cell Longevity
  doi: 10.1155/2013/925804
– volume: 68
  year: 2008
  ident: B229
  article-title: Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-5031
– volume: 234
  year: 2019
  ident: B281
  article-title: Thymoquinone-Induced Antitumor and Apoptosis in Human Lung Adenocarcinoma Cells
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.27710
– volume: 54
  start-page: 6
  year: 1994
  ident: B67
  article-title: Expression of Bcl-2 in Small Cell Lung Carcinoma Cells
  publication-title: Cancer Res
– volume: 34
  year: 2016
  ident: B353
  article-title: MET Exon 14 Mutations in non–Small-Cell Lung Cancer are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and C-Met Overexpression
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2015.63.4600
– volume: 26
  start-page: 1315
  year: 2021
  ident: B321
  article-title: Potential Therapeutic Targets of Quercetin, a Plant Flavonol, and its Role in the Therapy of Various Types of Cancer Through the Modulation of Various Cell Signaling Pathways
  publication-title: Molecules
  doi: 10.3390/molecules26051315
– volume: 17
  start-page: 299
  year: 2003
  ident: B279
  article-title: Pharmacological and Toxicological Properties of Nigella Sativa
  publication-title: Phytother Res
  doi: 10.1002/ptr.1309
– volume: 7
  year: 2001
  ident: B146
  article-title: Effects of Epigallocatechin-3-Gallate on Growth, Epidermal Growth Factor Receptor Signaling Pathways, Gene Expression, and Chemosensitivity in Human Head and Neck Squamous Cell Carcinoma Cell Lines
  publication-title: Clin Cancer Res
– volume: 65
  start-page: 18
  year: 2014
  ident: B248
  article-title: Thymoquinone Induces Heme Oxygenase-1 Expression in HaCaT Cells via Nrf2/ARE Activation: Akt and Ampkα as Upstream Targets
  publication-title: Food Chem Toxicol
  doi: 10.1016/j.fct.2013.12.015
– volume: 138
  year: 2008
  ident: B301
  article-title: Serum C-Reactive Protein Concentrations are Inversely Associated With Dietary Flavonoid Intake in US Adults
  publication-title: J Nutr
  doi: 10.1093/jn/138.4.753
– volume: 10
  start-page: 1
  year: 2010
  ident: B36
  article-title: Wnt Signal Transduction Pathway and Apoptosis: A Review
  publication-title: Cancer Cell Int
  doi: 10.1186/1475-2867-10-22
– volume: 3
  start-page: 296
  year: 2009
  ident: B286
  article-title: Thymoquinone Triggers Anti-Apoptotic Signaling Targeting Death Ligand and Apoptotic Regulators in a Model of Hepatic Ischemia Reperfusion Injury
  publication-title: Drug Discov Ther
– volume: 109
  year: 2007
  ident: B82
  article-title: Overexpression of Nucleolin in Chronic Lymphocytic Leukemia Cells Induces Stabilization of Bcl2 mRNA
  publication-title: Blood
  doi: 10.1182/blood-2006-08-043257
– volume: 362
  year: 2010
  ident: B120
  article-title: Gefitinib or Chemotherapy for non–Small-Cell Lung Cancer With Mutated EGFR
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0909530
– volume: 23
  year: 2005
  ident: B163
  article-title: Results From a Phase II, Open-Label, Randomized Study (SIGN) Comparing Gefitinib With Docetaxel as Second-Line Therapy in Patients With Advanced (Stage IIIb or IV) Non-Small-Cell Lung Cancer
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2005.23.16_suppl.7035
– volume: 255
  start-page: 6
  year: 1999
  ident: B272
  article-title: A Comparative Study of Apoptosis and Necrosis in HepG2 Cells: Oxidant-Induced Caspase Inactivation Leads to Necrosis
  publication-title: Biochem Biophys Res Commun
  doi: 10.1006/bbrc.1998.0139
– volume: 36
  year: 2016
  ident: B285
  article-title: Thymoquinone Induces Apoptosis Through Downregulation of C-FLIP and Bcl-2 in Renal Carcinoma Caki Cells
  publication-title: Oncol Rep
  doi: 10.3892/or.2016.5019
– volume: 61
  year: 2001
  ident: B88
  article-title: Up-Regulation of Bcl-2 in Microvascular Endothelial Cells Enhances Intratumoral Angiogenesis and Accelerates Tumor Growth
  publication-title: Cancer Res
– volume: 22
  start-page: 12162
  year: 2021
  ident: B198
  article-title: Therapeutic Potential of Ursolic Acid in Cancer and Diabetic Neuropathy Diseases
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms222212162
– volume: 124
  year: 2014
  ident: B331
  article-title: ABT-199 Mediated Inhibition of BCL-2 as a Novel Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia
  publication-title: Blood
  doi: 10.1182/blood-2014-05-574566
– volume: 280
  start-page: 119705
  year: 2021
  ident: B16
  article-title: Bcl-xL Expression and Regulation in the Progression, Recurrence, and Cisplatin Resistance of Oral Cancer
  publication-title: Life Sci
  doi: 10.1016/j.lfs.2021.119705
SSID ssj0000650103
Score 2.5134215
SecondaryResourceType review_article
Snippet Non-small cell lung carcinoma (NSCLC) comprises 80%–85% of lung cancer cases. EGFR is involved in several cancer developments, including NSCLC. The EGFR...
Non-small cell lung carcinoma (NSCLC) comprises 80%-85% of lung cancer cases. EGFR is involved in several cancer developments, including NSCLC. The EGFR...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 869672
SubjectTerms apoptosis
B cell lymphoma 2
Bax
NSCLC
Oncology
signaling
targeted therapy
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k14yUhcOIR1bCe2ubGrLgXRCpWt1Jvl-FGQlgR1t4L-e2bidNlFCC5cIuVteSae74vH3xDywgEnSCHJUgnlgKAwVrZepFJIERNPUWuJC5wPj5qDE_n-tD7dKvWFOWFZHjh33CTKAE5lghOVx7HTJcdgRyWngLfLFkdfiHlbZCqPwTUWMMjzksDCzCT1HSoWcv5KN6ZRfCcODXL9f8KYv6dKbsWe-S1ycwSN9E1u7G1yLXZ3yPXDcVr8Ljmbuh-TqV-WnM7cCjPe6bsVPc5l5mOg7SUFnEf3386P6UeAfN_d5Wu6-LXyii6GfHCIYrRP9Kjvyk9f3XJJZxE2H2A4gMeCc5zfIyfz_cXsoBwrKJS-5npd-kazljvjmDMVT6b2bRJ1EgZV9LxmKkYITsxXTYg-Ah2LrGmrgCXVU-u9FvfJXtd38SGh2mklk2hkA6AjAE1LGrChDkbUPkgpCzK56k_rR3lxrHKxtEAz0AIWLWDRAjZboCAvN3d8y9Iaf7l2iibaXIei2MMBcBU7uor9l6sU5PmVgS18RDgz4rrYX6wsoEID2I8rVpAH2eCbV-GPMcCodUHUjivstGX3TPfl8yDUDVyWKVU9-h-Nf0xuYH9g-huvn5C99flFfAp4aN0-G1z_J2nkBzU
  priority: 102
  providerName: Directory of Open Access Journals
Title Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/35402265
https://www.proquest.com/docview/2649256270
https://pubmed.ncbi.nlm.nih.gov/PMC8990771
https://doaj.org/article/e4d5789da31c4299afa0da37fa72024b
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELfQkBAviG_CYDISLzxkdWwndpAQotW6geiERiv1LXL8MZBCwtpOrP89d0nWUVQh8WLJieMkvjvf7-zzHSGvDdgEwQUZK6EMGCiMxaUVIRZS-MCD11riAefJaXYyk5_m6fzmeHQ_gMudph3mk5otqsOri_V7EPh3aHGCvh2EpsZghJwf6izPFEzIt0EvKRTTSQ_2u3k5xaQGmG2OCxnnUsy7fcudnWzpqTac_y4M-rcr5R-6aXyf3OtBJf3QccEDcsvXD8mdSb9t_oicD83VYGirmNORWaJHPP24pGddGnrvaLmmgAPp0fH4jH4BSPjLrN_S6c3JLDpt_cVBy9Em0NOmjr_-MFVFRx6KzzBdQLfAPIvHZDY-mo5O4j7DQmxTrlexzTQruckNM3nCQ57aMog0iByj7FnNlPegvJhNMuetB3PNs6xMHKZcD6W1Wjwhe3VT-2eEaqOVDCKTGYASB2Zc0IAdtctFap2UMiKD6_EsbB9-HLNgVAWYIUiBAilQIAWKjgIRebN54mcXeuMfbYdIok07DJrdXmgW50Uvg4WXDuan3BmRWFTDJhgGFRWMgq5kGZFX1wQuQMhw58TUvrlcFoAac8CGXLGIPO0IvnkVLpwBhk0jorZYYetbtu_U37-1gbzB1mVKJc__40f3yV2soRccT1-QvdXi0r8EWLQqD9rlBCiP58lBy_m_AbtXCYU
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bax%2FBcl-2+Cascade+Is+Regulated+by+the+EGFR+Pathway%3A+Therapeutic+Targeting+of+Non-Small+Cell+Lung+Cancer&rft.jtitle=Frontiers+in+oncology&rft.au=Alam%2C+Manzar&rft.au=Alam%2C+Shoaib&rft.au=Shamsi%2C+Anas&rft.au=Adnan%2C+Mohd&rft.date=2022-03-25&rft.issn=2234-943X&rft.eissn=2234-943X&rft.volume=12&rft_id=info:doi/10.3389%2Ffonc.2022.869672&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fonc_2022_869672
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon